E2F-1	B-protein
and	O
a	O
cyclin-like	B-protein
DNA	I-protein
repair	I-protein
enzyme	I-protein
,	O
uracil-DNA	B-protein
glycosylase	I-protein
,	O
provide	O
evidence	O
for	O
an	O
autoregulatory	O
mechanism	O
for	O
transcription	O
.	O

The	O
cell	B-protein
cycle-dependent	I-protein
transcription	I-protein
factor	I-protein
,	O
E2F-1	B-protein
,	O
regulates	O
the	O
cyclin	B-protein
-like	O
species	O
of	O
the	O
DNA	B-protein
repair	I-protein
enzyme	I-protein
uracil-DNA	B-DNA
glycosylase	I-DNA
(	I-DNA
UDG	I-DNA
)	I-DNA
gene	I-DNA
in	O
human	B-cell_line
osteosarcoma	I-cell_line
(	I-cell_line
Saos-2	I-cell_line
)	I-cell_line
cells	I-cell_line
.	O

We	O
demonstrate	O
,	O
through	O
the	O
deletion	O
of	O
the	O
human	B-DNA
UDG	I-DNA
promoter	I-DNA
sequences	I-DNA
,	O
that	O
expression	O
of	O
E2F-1	B-protein
activates	O
the	O
UDG	B-DNA
promoter	I-DNA
through	O
several	O
E2F	B-DNA
sites	I-DNA
.	O

The	O
major	B-DNA
putative	I-DNA
downstream	I-DNA
site	I-DNA
for	O
E2F	B-protein
,	O
located	O
in	O
the	O
first	B-DNA
exon	I-DNA
,	O
serves	O
as	O
a	O
target	O
for	O
E2F-1/DP1	B-protein
complex	I-protein
binding	O
in	O
vitro	O
.	O

We	O
also	O
provide	O
evidence	O
for	O
the	O
functional	O
relationship	O
between	O
the	O
cyclin-like	B-protein
UDG	I-protein
gene	I-protein
product	I-protein
and	O
E2F	B-protein
.	O

High	O
levels	O
of	O
UDG	B-protein
expression	O
in	O
a	O
transient	O
transfection	O
assay	O
result	O
in	O
the	O
down-regulation	O
of	O
transcriptional	O
activity	O
through	O
elements	B-DNA
specific	O
for	O
E2F	B-protein
-mediated	O
transcription	O
.	O

Overexpression	O
of	O
UDG	B-protein
in	O
Saos	B-cell_line
2	I-cell_line
cells	I-cell_line
was	O
observed	O
to	O
delay	O
growth	O
late	O
in	O
G1	O
phase	O
and	O
transiently	O
arrest	O
these	O
cells	O
from	O
progressing	O
into	O
the	O
S	O
phase	O
.	O

This	O
hypothetical	O
model	O
integrates	O
one	O
mechanism	O
of	O
DNA	O
repair	O
with	O
the	O
cell	O
cycle	O
control	O
of	O
gene	O
transcription	O
,	O
likely	O
through	O
E2F	B-protein
.	O

This	O
implicates	O
E2F	B-protein
as	O
a	O
multifunctional	O
target	O
for	O
proteins	O
and	O
enzymes	O
,	O
possibly	O
,	O
responsive	O
to	O
DNA	O
damage	O
through	O
the	O
negative	O
effect	O
of	O
UDG	B-protein
on	O
E2F	B-protein
-mediated	O
transcriptional	O
activity	O
.	O

THE	NULL
JouRNaL	NULL
or	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
©	NULL
1995	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

270	NULL
,	NULL
No	NULL
.	NULL

10	NULL
,	NULL
Issue	NULL
of	NULL
March	NULL
10	NULL
,	NULL
pp	NULL
.	NULL

5289-5298	NULL
,	NULL
1995	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
E2F-1	NULL
and	NULL
a	NULL
Cyclin-like	NULL
DNA	NULL
Repair	NULL
Enzyme	NULL
,	NULL
Uracil-DNA	NULL
Glycosylase	NULL
,	NULL
Provide	NULL
Evidence	NULL
for	NULL
an	NULL
Autoregulatory	NULL
Mechanism	NULL
for	NULL
Transcription*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
October	NULL
19	NULL
,	NULL
1994	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
December	NULL
16	NULL
,	NULL
1994	NULL
)	NULL
Martin	NULL
J.	NULL
Walsh	NULL
}	NULL
,	NULL
Gongliang	NULL
Shue	NULL
,	NULL
Kathy	NULL
Spidoni	NULL
$	NULL
§	NULL
,	NULL
and	NULL
Ajoy	NULL
Kapoor	NULL
!	NULL

From	NULL
the	NULL
Department	NULL
of	NULL
Pediatrics	NULL
,	NULL
Mount	NULL
Sinai	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
New	NULL
York	NULL
,	NULL
New	NULL
York	NULL
10029	NULL
The	NULL
cell	NULL
cycle-dependent	NULL
transcription	NULL
factor	NULL
,	NULL
E2F-1	NULL
,	NULL
regulates	NULL
the	NULL
cyclin-like	NULL
species	NULL
of	NULL
the	NULL
DNA	NULL
repair	NULL
enzyme	NULL
uracil-DNA	NULL
glycosylase	NULL
(	NULL
UDG	NULL
)	NULL
gene	NULL
in	NULL
human	NULL
osteosarcoma	NULL
(	NULL
Saos-2	NULL
)	NULL
cells	NULL
.	NULL

We	NULL
demonstrate	NULL
,	NULL
through	NULL
the	NULL
deletion	NULL
of	NULL
the	NULL
human	NULL
UDG	NULL
promoter	NULL
sequences	NULL
,	NULL
that	NULL
expression	NULL
of	NULL
E2F-1	NULL
activates	NULL
the	NULL
UDG	NULL
promoter	NULL
through	NULL
several	NULL
E2F	NULL
sites	NULL
.	NULL

The	NULL
major	NULL
putative	NULL
downstream	NULL
site	NULL
for	NULL
E2F	NULL
,	NULL
located	NULL
in	NULL
the	NULL
first	NULL
exon	NULL
,	NULL
serves	NULL
as	NULL
a	NULL
target	NULL
for	NULL
E2F-1/DP1	NULL
complex	NULL
binding	NULL
in	NULL
vitro	NULL
.	NULL

We	NULL
also	NULL
provide	NULL
evidence	NULL
for	NULL
the	NULL
functional	NULL
relationship	NULL
between	NULL
the	NULL
cyclin-like	NULL
UDG	NULL
gene	NULL
product	NULL
and	NULL
E2F	NULL
.	NULL

High	NULL
levels	NULL
of	NULL
UDG	NULL
expression	NULL
in	NULL
a	NULL
transient	NULL
transfection	NULL
assay	NULL
result	NULL
in	NULL
the	NULL
down-regulation	NULL
of	NULL
transcriptional	NULL
activity	NULL
through	NULL
elements	NULL
specific	NULL
for	NULL
E2F-mediated	NULL
transcription	NULL
.	NULL

Overexpression	NULL
of	NULL
UDG	NULL
in	NULL
Saos	NULL
2	NULL
cells	NULL
was	NULL
observed	NULL
to	NULL
delay	NULL
growth	NULL
late	NULL
in	NULL
G	NULL
,	NULL
phase	NULL
and	NULL
transiently	NULL
arrest	NULL
these	NULL
cells	NULL
from	NULL
progressing	NULL
into	NULL
the	NULL
S	NULL
phase	NULL
.	NULL

This	NULL
hypothetical	NULL
model	NULL
integrates	NULL
one	NULL
mechanism	NULL
of	NULL
DNA	NULL
repair	NULL
with	NULL
the	NULL
cell	NULL
cycle	NULL
control	NULL
of	NULL
gene	NULL
transcription	NULL
,	NULL
likely	NULL
through	NULL
EZF	NULL
.	NULL

This	NULL
implicates	NULL
E2F	NULL
as	NULL
a	NULL
multifunctional	NULL
target	NULL
for	NULL
proteins	NULL
and	NULL
enzymes	NULL
,	NULL
possibly	NULL
,	NULL
responsive	NULL
to	NULL
DNA	NULL
damage	NULL
through	NULL
the	NULL
negative	NULL
effect	NULL
of	NULL
UDG	NULL
on	NULL
E2F-mediated	NULL
transcriptional	NULL
activity	NULL
.	NULL

The	NULL
gene	NULL
for	NULL
a	NULL
novel	NULL
uracil-DNA	NULL
glycosylase	NULL
(	NULL
UDG	NULL
)	NULL
has	NULL
recently	NULL
been	NULL
cloned	NULL
and	NULL
characterized	NULL
by	NULL
DNA	NULL
sequence	NULL
analysis	NULL
(	NULL
1	NULL
)	NULL
.	NULL

The	NULL
enzyme	NULL
activity	NULL
of	NULL
uracil-DNA	NULL
glycosylase	NULL
includes	NULL
the	NULL
hydrolysis	NULL
of	NULL
the	NULL
N-glycosyl	NULL
bond	NULL
from	NULL
a	NULL
uracil	NULL
residue	NULL
incorporated	NULL
into	NULL
the	NULL
DNA	NULL
strand	NULL
to	NULL
produce	NULL
a	NULL
free	NULL
base	NULL
(	NULL
2	NULL
)	NULL
.	NULL

The	NULL
subsequent	NULL
apyrimdinic	NULL
site	NULL
is	NULL
cleaved	NULL
by	NULL
specific	NULL
endo-nucleotidy	NULL
]	NULL
activity	NULL
with	NULL
the	NULL
resulting	NULL
gap	NULL
filled	NULL
by	NULL
DNA	NULL
polymerase	NULL
B	NULL
(	NULL
for	NULL
review	NULL
see	NULL
Ref	NULL
.	NULL

3	NULL
)	NULL
.	NULL

The	NULL
regulation	NULL
and	NULL
struc-	NULL
*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
a	NULL
Public	NULL
Health	NULL
Service	NULL
Award	NULL
from	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

+	NULL
To	NULL
whom	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
Dept	NULL
.	NULL

of	NULL
Pediatrics	NULL
,	NULL
Mount	NULL
Sinai	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
One	NULL
Gustave	NULL
L.	NULL
Levy	NULL
Place	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
10029	NULL
.	NULL

Tel	NULL
:	NULL
212-241-9714	NULL
;	NULL
Email	NULL
:	NULL
walsh	NULL
@	NULL
vax	NULL
.	NULL

mssm	NULL
.	NULL

edu	NULL
.	NULL

§	NULL
Supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Training	NULL
Fellowship	NULL
AMO7420	NULL
.	NULL

4	NULL
Supported	NULL
by	NULL
a	NULL
medical	NULL
student	NULL
research	NULL
training	NULL
fellowship	NULL
from	NULL
the	NULL
Society	NULL
for	NULL
Pediatric	NULL
Research	NULL
.	NULL

*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
UDG	NULL
,	NULL
uracil-DNA	NULL
glycosylase	NULL
;	NULL
TLCK	NULL
,	NULL
Na-p-togyl-L-lysine	NULL
chloromethyl	NULL
ketone	NULL
;	NULL
TPCK	NULL
,	NULL
N-tosyl-L-phenylala-nine	NULL
chloromethyl	NULL
ketone	NULL
;	NULL
PAGE	NULL
,	NULL
polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
;	NULL
GST	NULL
,	NULL
bacterial	NULL
glutathione	NULL
S-transferase	NULL
leader	NULL
peptide	NULL
;	NULL
MBP	NULL
,	NULL
malE	NULL
maltose-binding	NULL
protein	NULL
;	NULL
EMSA	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay/	NULL
band	NULL
shift	NULL
mobility	NULL
assay	NULL
;	NULL
DTT	NULL
,	NULL
dithiothreitol	NULL
;	NULL
PCR	NULL
,	NULL
polymerase	NULL
chain	NULL
reaction	NULL
;	NULL
CAT	NULL
,	NULL
chloramphenicol	NULL
acetyltransferase	NULL
;	NULL
CMV	NULL
,	NULL
cytomegalo-virus	NULL
.	NULL

tural	NULL
relationship	NULL
of	NULL
the	NULL
nuclear	NULL
UDG	NULL
gene	NULL
product	NULL
to	NULL
the	NULL
cyclin	NULL
family	NULL
of	NULL
cellular	NULL
factors	NULL
share	NULL
many	NULL
common	NULL
characteristics	NULL
(	NULL
4	NULL
)	NULL
.	NULL

The	NULL
cell	NULL
cyele-dependent	NULL
expression	NULL
of	NULL
UDG	NULL
parallels	NULL
that	NULL
of	NULL
several	NULL
cyclin	NULL
and	NULL
associated	NULL
edk	NULL
gene	NULL
products	NULL
(	NULL
4	NULL
)	NULL
.	NULL

The	NULL
entire	NULL
structural	NULL
gene	NULL
for	NULL
UDG	NULL
has	NULL
also	NULL
been	NULL
characterized	NULL
,	NULL
with	NULL
the	NULL
limits	NULL
of	NULL
promoter	NULL
activity	NULL
defined	NULL
by	NULL
deletion	NULL
analysis	NULL
of	NULL
the	NULL
5	NULL
end	NULL
of	NULL
the	NULL
structural	NULL
gene	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Implication	NULL
that	NULL
cell	NULL
cycle	NULL
regulation	NULL
of	NULL
UDG	NULL
gene	NULL
transcription	NULL
is	NULL
mediated	NULL
by	NULL
E2F	NULL
is	NULL
supported	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
several	NULL
putative	NULL
E2F	NULL
cognate	NULL
sequences	NULL
dispersed	NULL
throughout	NULL
the	NULL
promoter	NULL
region	NULL
(	NULL
4	NULL
)	NULL
.	NULL

The	NULL
recent	NULL
characterization	NULL
of	NULL
events	NULL
that	NULL
occur	NULL
during	NULL
the	NULL
cell	NULL
cycle	NULL
has	NULL
implicated	NULL
E2F	NULL
as	NULL
a	NULL
central	NULL
mediator	NULL
of	NULL
transcriptional	NULL
control	NULL
.	NULL

E2F	NULL
was	NULL
initially	NULL
identified	NULL
as	NULL
a	NULL
cellular	NULL
factor	NULL
mediating	NULL
gene	NULL
transcription	NULL
of	NULL
the	NULL
adenovirus	NULL
E2	NULL
early	NULL
gene	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Since	NULL
then	NULL
,	NULL
many	NULL
studies	NULL
have	NULL
provided	NULL
evidence	NULL
for	NULL
the	NULL
direct	NULL
role	NULL
of	NULL
E2F	NULL
as	NULL
a	NULL
cellular	NULL
factor	NULL
required	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
genes	NULL
necessary	NULL
for	NULL
the	NULL
progression	NULL
into	NULL
the	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
(	NULL
6	NULL
,	NULL
7	NULL
)	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
E2F	NULL
is	NULL
mediated	NULL
by	NULL
the	NULL
direct	NULL
interaction	NULL
with	NULL
the	NULL
wild-type	NULL
retinoblastoma	NULL
susceptibility	NULL
gene	NULL
product	NULL
(	NULL
Rb	NULL
)	NULL
(	NULL
8	NULL
)	NULL
and	NULL
the	NULL
Rb-related	NULL
gene	NULL
product	NULL
,	NULL
p107	NULL
(	NULL
9	NULL
)	NULL
.	NULL

The	NULL
transcriptional	NULL
activity	NULL
of	NULL
E2F	NULL
is	NULL
regulated	NULL
through	NULL
the	NULL
interactions	NULL
with	NULL
the	NULL
Rb	NULL
gene	NULL
product	NULL
and	NULL
p107	NULL
in	NULL
a	NULL
cell	NULL
cycle-restricted	NULL
manner	NULL
(	NULL
10	NULL
,	NULL
11	NULL
)	NULL
.	NULL

These	NULL
interactions	NULL
complex	NULL
E2F	NULL
with	NULL
other	NULL
cell	NULL
cycle-mediated	NULL
factors	NULL
,	NULL
cyclins	NULL
A	NULL
and	NULL
E	NULL
as	NULL
well	NULL
as	NULL
cyclin-dependent	NULL
kinase	NULL
,	NULL
cdk	NULL
2	NULL
(	NULL
12-16	NULL
)	NULL
.	NULL

It	NULL
is	NULL
considered	NULL
that	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
normal	NULL
Rb	NULL
function	NULL
unsequestered	NULL
E2F	NULL
activity	NULL
goes	NULL
unchecked	NULL
and	NULL
,	NULL
therefore	NULL
,	NULL
allows	NULL
unrestricted	NULL
activation	NULL
of	NULL
many	NULL
genes	NULL
required	NULL
for	NULL
cell	NULL
proliferation	NULL
.	NULL

This	NULL
includes	NULL
many	NULL
putative	NULL
protooncogene	NULL
products	NULL
and	NULL
cytokines	NULL
responsible	NULL
for	NULL
cell	NULL
transformation	NULL
(	NULL
i.e	NULL
.	NULL

c-myc	NULL
,	NULL
c-myb	NULL
,	NULL
transforming	NULL
growth	NULL
factor	NULL
B1	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
a	NULL
mechanism	NULL
for	NULL
the	NULL
deregulated	NULL
activity	NULL
of	NULL
E2F	NULL
apparently	NULL
contributes	NULL
to	NULL
the	NULL
oncogenic	NULL
potential	NULL
associated	NULL
with	NULL
many	NULL
DNA	NULL
tumor	NULL
viruses	NULL
(	NULL
18-20	NULL
)	NULL
.	NULL

Gene	NULL
products	NULL
of	NULL
many	NULL
DNA	NULL
tumor	NULL
viruses	NULL
can	NULL
actively	NULL
compete	NULL
for	NULL
the	NULL
same	NULL
binding	NULL
domain	NULL
of	NULL
the	NULL
Rb	NULL
gene	NULL
product	NULL
as	NULL
E2F	NULL
.	NULL

Therefore	NULL
,	NULL
this	NULL
inhibition	NULL
of	NULL
E2F	NULL
binding	NULL
to	NULL
Rb	NULL
results	NULL
in	NULL
free	NULL
E2F	NULL
and	NULL
subsequent	NULL
activation	NULL
of	NULL
many	NULL
genes	NULL
responsible	NULL
for	NULL
cell	NULL
growth	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
specific	NULL
E2F	NULL
activity	NULL
has	NULL
been	NULL
cloned	NULL
by	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
recombinant	NULL
expression	NULL
of	NULL
cDNAs	NULL
to	NULL
interact	NULL
with	NULL
the	NULL
Rb	NULL
protein	NULL
(	NULL
21	NULL
)	NULL
and	NULL
identifying	NULL
one	NULL
novel	NULL
cDNA	NULL
encoding	NULL
E2F-1	NULL
(	NULL
22-24	NULL
)	NULL
.	NULL

The	NULL
identification	NULL
of	NULL
the	NULL
E2F-1	NULL
gene	NULL
has	NULL
made	NULL
available	NULL
an	NULL
approach	NULL
to	NULL
study	NULL
the	NULL
activation	NULL
of	NULL
suspect	NULL
target	NULL
genes	NULL
by	NULL
E2F-1	NULL
.	NULL

Despite	NULL
the	NULL
identification	NULL
of	NULL
one	NULL
E2F-specific	NULL
gene	NULL
product	NULL
,	NULL
recent	NULL
evidence	NULL
to	NULL
suggest	NULL
that	NULL
E2F	NULL
exists	NULL
as	NULL
a	NULL
multiple	NULL
heteromeric	NULL
complex	NULL
has	NULL
been	NULL
established	NULL
by	NULL
the	NULL
cloning	NULL
and	NULL
characterization	NULL
of	NULL
additional	NULL
members	NULL
of	NULL
the	NULL
E2F	NULL
family	NULL
of	NULL
cellular	NULL
transcription	NULL
factors	NULL
(	NULL
25	NULL
,	NULL
26	NULL
)	NULL
including	NULL
the	NULL
heterodimeric	NULL
partner	NULL
of	NULL
E2F-1	NULL
,	NULL
DPI	NULL
(	NULL
27	NULL
,	NULL
28	NULL
)	NULL
.	NULL

Here	NULL
we	NULL
take	NULL
advantage	NULL
of	NULL
the	NULL
cloned	NULL
E2F-1	NULL
protein	NULL
to	NULL
examine	NULL
the	NULL
role	NULL
E2F	NULL
has	NULL
in	NULL
transactivating	NULL
the	NULL
transcription	NULL
of	NULL
a	NULL
novel	NULL
cell	NULL
cycle-regulated	NULL
DNA	NULL
repair	NULL
enzyme	NULL
.	NULL

We	NULL
demon	NULL
5289	NULL
5290	NULL
strate	NULL
that	NULL
putative	NULL
E2F	NULL
sites	NULL
,	NULL
localized	NULL
within	NULL
the	NULL
UDG	NULL
promoter	NULL
,	NULL
contribute	NULL
to	NULL
the	NULL
transactivation	NULL
of	NULL
UDG	NULL
gene	NULL
transcription	NULL
and	NULL
that	NULL
the	NULL
major	NULL
site	NULL
for	NULL
E2F	NULL
transactivation	NULL
is	NULL
localized	NULL
in	NULL
an	NULL
EZF	NULL
consensus	NULL
sequence	NULL
within	NULL
the	NULL
first	NULL
exon	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
have	NULL
identified	NULL
this	NULL
sequence	NULL
as	NULL
a	NULL
specific	NULL
target	NULL
for	NULL
E2F-1/DP1	NULL
binding	NULL
in	NULL
vitro	NULL
.	NULL

Because	NULL
of	NULL
the	NULL
closest	NULL
relative	NULL
homology	NULL
of	NULL
this	NULL
nuclear	NULL
species	NULL
of	NULL
UDG	NULL
to	NULL
the	NULL
cyclin	NULL
A	NULL
protein	NULL
,	NULL
we	NULL
tested	NULL
the	NULL
possibility	NULL
that	NULL
this	NULL
UDG	NULL
gene	NULL
product	NULL
modulates	NULL
E2F-1	NULL
activity	NULL
through	NULL
an	NULL
E2F-responsive	NULL
target	NULL
.	NULL

Although	NULL
the	NULL
precise	NULL
cellular	NULL
connection	NULL
of	NULL
cyclin	NULL
A-edk	NULL
2	NULL
and	NULL
E2F	NULL
is	NULL
still	NULL
not	NULL
clearly	NULL
established	NULL
,	NULL
the	NULL
interaction	NULL
between	NULL
cyclin	NULL
A-edk2	NULL
and	NULL
E2F	NULL
has	NULL
been	NULL
recently	NULL
shown	NULL
to	NULL
have	NULL
a	NULL
negative	NULL
role	NULL
on	NULL
E2F-mediated	NULL
function	NULL
(	NULL
29	NULL
)	NULL
.	NULL

This	NULL
is	NULL
likely	NULL
an	NULL
important	NULL
component	NULL
for	NULL
the	NULL
progression	NULL
of	NULL
mitotic	NULL
events	NULL
.	NULL

We	NULL
have	NULL
demonstrated	NULL
here	NULL
the	NULL
ability	NULL
of	NULL
this	NULL
nuclear	NULL
``	NULL
cyclin-like	NULL
``	NULL
species	NULL
of	NULL
UDG	NULL
to	NULL
repress	NULL
the	NULL
activity	NULL
of	NULL
E2F-mediated	NULL
transcription	NULL
in	NULL
a	NULL
cotransfection	NULL
assay	NULL
.	NULL

The	NULL
likelihood	NULL
of	NULL
cellular	NULL
factors	NULL
involved	NULL
in	NULL
DNA	NULL
repair	NULL
,	NULL
possibly	NULL
analogous	NULL
to	NULL
the	NULL
role	NULL
cyclins	NULL
may	NULL
have	NULL
in	NULL
mediating	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
EZF	NULL
,	NULL
may	NULL
represent	NULL
alternative	NULL
pathways	NULL
regulating	NULL
E2F	NULL
function	NULL
,	NULL
thereby	NULL
competing	NULL
for	NULL
the	NULL
control	NULL
of	NULL
cell	NULL
cycle	NULL
events	NULL
necessary	NULL
for	NULL
the	NULL
restoration	NULL
of	NULL
damaged	NULL
DNA	NULL
.	NULL

A	NULL
major	NULL
focus	NULL
in	NULL
several	NULL
recent	NULL
genetic	NULL
and	NULL
biochemical	NULL
studies	NULL
is	NULL
the	NULL
intersecting	NULL
relationship	NULL
between	NULL
DNA	NULL
repair	NULL
and	NULL
transcriptional	NULL
control	NULL
.	NULL

Many	NULL
proposed	NULL
mechanisms	NULL
have	NULL
suggested	NULL
that	NULL
common	NULL
factors	NULL
associated	NULL
with	NULL
both	NULL
DNA	NULL
repair	NULL
and	NULL
gene	NULL
transcription	NULL
are	NULL
functionally	NULL
related	NULL
(	NULL
30	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
role	NULL
that	NULL
the	NULL
tumor	NULL
suppressor	NULL
gene	NULL
product	NULL
p53	NULL
has	NULL
in	NULL
both	NULL
transcriptional	NULL
control	NULL
and	NULL
response	NULL
to	NULL
damaged	NULL
DNA	NULL
(	NULL
31	NULL
)	NULL
is	NULL
unique	NULL
in	NULL
our	NULL
understanding	NULL
of	NULL
the	NULL
complex	NULL
pathways	NULL
that	NULL
integrate	NULL
gene	NULL
transcription	NULL
with	NULL
specific	NULL
factors	NULL
necessary	NULL
for	NULL
DNA	NULL
repair	NULL
.	NULL

We	NULL
suggest	NULL
one	NULL
mechanism	NULL
that	NULL
implicates	NULL
E2F-mediated	NULL
transcription	NULL
in	NULL
modulating	NULL
a	NULL
cellular	NULL
factor	NULL
involved	NULL
in	NULL
DNA	NULL
repair	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Plasmid	NULL
Constructions-The	NULL
5'-flanking	NULL
region	NULL
of	NULL
the	NULL
human	NULL
UDG	NULL
gene	NULL
from	NULL
-1389	NULL
to	NULL
+81	NULL
,	NULL
relative	NULL
to	NULL
the	NULL
site	NULL
of	NULL
transcriptional	NULL
initia-tion	NULL
,	NULL
was	NULL
obtained	NULL
through	NULL
cloning	NULL
of	NULL
the	NULL
DNA	NULL
fragment	NULL
from	NULL
normal	NULL
human	NULL
liver	NULL
genomic	NULL
DNA	NULL
using	NULL
the	NULL
polymerase	NULL
chain	NULL
reaction	NULL
(	NULL
PCR	NULL
)	NULL
with	NULL
Vent	NULL
,	NULL
®	NULL
DNA	NULL
polymerase	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

Oligonucleotide	NULL
primer	NULL
sequences	NULL
were	NULL
obtained	NULL
from	NULL
previously	NULL
published	NULL
sequences	NULL
(	NULL
4	NULL
)	NULL
,	NULL
which	NULL
included	NULL
restriction	NULL
adaptor	NULL
sequences	NULL
to	NULL
facilitate	NULL
subcloning	NULL
of	NULL
the	NULL
DNA	NULL
fragments	NULL
.	NULL

The	NULL
DNA	NULL
fragments	NULL
containing	NULL
the	NULL
1.4	NULL
kilobases	NULL
of	NULL
the	NULL
5'-flanking	NULL
region	NULL
of	NULL
the	NULL
UDG	NULL
gene	NULL
and	NULL
series	NULL
of	NULL
deletions	NULL
were	NULL
generated	NULL
and	NULL
cloned	NULL
directly	NULL
upstream	NULL
of	NULL
the	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
gene	NULL
in	NULL
the	NULL
Xbal	NULL
site	NULL
of	NULL
plasmid	NULL
vector	NULL
pCAT	NULL
(	NULL
Promega	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

Progressive	NULL
deletions	NULL
from	NULL
the	NULL
5	NULL
'	NULL
end	NULL
of	NULL
the	NULL
UDG	NULL
gene	NULL
promoter	NULL
were	NULL
engineered	NULL
by	NULL
the	NULL
same	NULL
PCR-based	NULL
method	NULL
using	NULL
specific	NULL
oligonucleotide	NULL
sequences	NULL
corresponding	NULL
to	NULL
selected	NULL
end	NULL
points	NULL
of	NULL
the	NULL
UDG	NULL
gene	NULL
promoter	NULL
region	NULL
.	NULL

The	NULL
5	NULL
'	NULL
deletion	NULL
mutants	NULL
designated	NULL
UDG	NULL
construct-A	NULL
,	NULL
UDG	NULL
construct-B	NULL
,	NULL
UDG	NULL
construct-C	NULL
,	NULL
UDG	NULL
construct-D/wt	NULL
,	NULL
and	NULL
UDG	NULL
construct-F	NULL
were	NULL
designed	NULL
to	NULL
remove	NULL
specific	NULL
E2F	NULL
and	NULL
Sp1	NULL
cognate	NULL
elements	NULL
from	NULL
the	NULL
UDG	NULL
promoter	NULL
by	NULL
this	NULL
method	NULL
.	NULL

Deletion	NULL
mutant	NULL
UDG	NULL
construct-E	NULL
was	NULL
engineered	NULL
by	NULL
digesting	NULL
plasmid	NULL
minigene	NULL
UDG	NULL
construct-D/wt	NULL
with	NULL
Xbal	NULL
,	NULL
treated	NULL
with	NULL
Escherichia	NULL
coli	NULL
Exonuclease	NULL
III	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
,	NULL
Inc.	NULL
)	NULL
,	NULL
then	NULL
blunt	NULL
ended	NULL
with	NULL
mung	NULL
bean	NULL
nuclease	NULL
and	NULL
E.	NULL
coli	NULL
DNA	NULL
polymerase	NULL
I	NULL
(	NULL
large	NULL
fragment	NULL
)	NULL
enzyme	NULL
all	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

The	NULL
DNA	NULL
was	NULL
recircularized	NULL
with	NULL
T4	NULL
DNA	NULL
ligase	NULL
enzyme	NULL
to	NULL
produce	NULL
circular	NULL
plasmid	NULL
DNA	NULL
.	NULL

Plasmid	NULL
expression	NULL
vectors	NULL
for	NULL
E2F-1	NULL
and	NULL
UDG	NULL
were	NULL
generated	NULL
by	NULL
subcloning	NULL
cDNA	NULL
coding	NULL
region	NULL
fragments	NULL
into	NULL
the	NULL
expression	NULL
vector	NULL
peDNA3	NULL
(	NULL
Invitrogen®	NULL
)	NULL
.	NULL

The	NULL
B2F-1	NULL
and	NULL
UDG	NULL
plasmid	NULL
cDNAs	NULL
were	NULL
generously	NULL
provided	NULL
by	NULL
William	NULL
Kaelin	NULL
(	NULL
Dana-Farber	NULL
Cancer	NULL
Center	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
and	NULL
Sal	NULL
Caradonna	NULL
(	NULL
University	NULL
of	NULL
Medicine	NULL
and	NULL
Dentistry	NULL
of	NULL
New	NULL
Jersey	NULL
,	NULL
Stratford	NULL
,	NULL
NJ	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
plasmids	NULL
provided	NULL
appropriate	NULL
DNA	NULL
fragments	NULL
to	NULL
subclone	NULL
both	NULL
the	NULL
E2F-1	NULL
and	NULL
UDG	NULL
cDNAs	NULL
into	NULL
peDNA3	NULL
.	NULL

Expression	NULL
vector	NULL
pCMV/EZF-1	NULL
was	NULL
generated	NULL
by	NULL
digesting	NULL
the	NULL
E2F	NULL
cDNA	NULL
with	NULL
BamHI	NULL
and	NULL
EcoRI	NULL
subcloned	NULL
unidirec-tionally	NULL
into	NULL
the	NULL
BamH/EcoRI-treated	NULL
peDNA3	NULL
plasmid	NULL
.	NULL

The	NULL
expression	NULL
vector	NULL
pCMV/UDGa	NULL
was	NULL
similarly	NULL
subcloned	NULL
by	NULL
insertion	NULL
of	NULL
the	NULL
The	NULL
UDG	NULL
Gene	NULL
Product	NULL
Inhibits	NULL
E2F-1-mediated	NULL
Transcription	NULL
UDG	NULL
cDNA	NULL
EcoRI	NULL
fragment	NULL
into	NULL
the	NULL
EcoRI	NULL
site	NULL
of	NULL
pcDNA3	NULL
.	NULL

The	NULL
orientation	NULL
and	NULL
complete	NULL
promoter	NULL
sequence	NULL
of	NULL
the	NULL
reporter	NULL
minigene	NULL
constructs	NULL
were	NULL
confirmed	NULL
by	NULL
nucleotide	NULL
sequence	NULL
analysis	NULL
using	NULL
Sequenase®	NULL
II	NULL
kit	NULL
(	NULL
United	NULL
States	NULL
Biochemicals	NULL
Corp.	NULL
,	NULL
Cleveland	NULL
,	NULL
OH	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

The	NULL
cloning	NULL
of	NULL
E2F-1	NULL
and	NULL
UDG	NULL
cDNA	NULL
inserts	NULL
into	NULL
expression	NULL
vector	NULL
pcDNA3	NULL
were	NULL
also	NULL
verified	NULL
the	NULL
complete	NULL
cDNA	NULL
sequence	NULL
by	NULL
the	NULL
dideoxynucleotide	NULL
chain	NULL
termination	NULL
method	NULL
of	NULL
DNA	NULL
sequencing	NULL
also	NULL
using	NULL
Sequenase®	NULL
II	NULL
kit	NULL
.	NULL

Site-directed	NULL
Mutagenesis-Mutation	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
promoter	NULL
sequence	NULL
to	NULL
generate	NULL
plasmid	NULL
minigene	NULL
UDG	NULL
construct-D/mut	NULL
was	NULL
directed	NULL
by	NULL
a	NULL
PCR-based	NULL
method	NULL
(	NULL
82	NULL
)	NULL
.	NULL

The	NULL
oligonucleotide	NULL
primers	NULL
to	NULL
generate	NULL
point	NULL
mutations	NULL
,	NULL
indicated	NULL
by	NULL
underlined	NULL
nucleotide	NULL
bases	NULL
,	NULL
in	NULL
the	NULL
E2F	NULL
recognition	NULL
sequence	NULL
were	NULL
synthesized	NULL
and	NULL
the	NULL
sequences	NULL
are	NULL
shown	NULL
as	NULL
follows	NULL
:	NULL
A	NULL
,	NULL
5-CCTCTAGACTCAGGGGTGTAAATAACTT-GCCCGAGTTCGGTAGGAGTCCAGACTCAACCGGGAGACGCTCG-	NULL
B	NULL
,	NULL
5-GCCCGGGCCCGCGACAGCCCAGCGT-3	NULL
'	NULL
.	NULL

The	NULL
template	NULL
for	NULL
the	NULL
PCR	NULL
was	NULL
plasmid	NULL
UDG-construct-D/wt	NULL
.	NULL

The	NULL
239-base	NULL
pair	NULL
PCR	NULL
product	NULL
was	NULL
digested	NULL
with	NULL
Apal	NULL
and	NULL
Xbal	NULL
and	NULL
subcloned	NULL
back	NULL
into	NULL
the	NULL
backbone	NULL
fragment	NULL
to	NULL
replace	NULL
the	NULL
wild	NULL
type	NULL
Apal/Xbal	NULL
fragment	NULL
of	NULL
UDG	NULL
construct-D/wt	NULL
with	NULL
the	NULL
mutation	NULL
to	NULL
generate	NULL
minigene	NULL
UDG	NULL
construct-D/mut	NULL
.	NULL

All	NULL
the	NULL
mutations	NULL
were	NULL
confirmed	NULL
by	NULL
chain	NULL
termination	NULL
method	NULL
of	NULL
DNA	NULL
sequencing	NULL
using	NULL
Sequenase®	NULL
II	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

Cell	NULL
Culture	NULL
and	NULL
Transfection	NULL
Assays-Human	NULL
Saos	NULL
2	NULL
(	NULL
osteosar-coma	NULL
)	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
McCoy	NULL
's	NULL
5a	NULL
medium	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
2	NULL
mM	NULL
glutamine	NULL
and	NULL
gentamicin	NULL
(	NULL
100	NULL
ug/ml	NULL
)	NULL
.	NULL

Transfection	NULL
assays	NULL
were	NULL
performed	NULL
by	NULL
calcium	NULL
phosphate	NULL
precipitation	NULL
as	NULL
described	NULL
in	NULL
detail	NULL
(	NULL
33	NULL
)	NULL
.	NULL

All	NULL
plasmid	NULL
DNAs	NULL
were	NULL
purified	NULL
by	NULL
two	NULL
repetitive	NULL
CsCl	NULL
gradient	NULL
centrifugations	NULL
to	NULL
obtain	NULL
supercoiled	NULL
DNA	NULL
.	NULL

Each	NULL
transfection	NULL
was	NULL
carried	NULL
out	NULL
in	NULL
parallel	NULL
using	NULL
at	NULL
least	NULL
two	NULL
separate	NULL
plasmid	NULL
DNA	NULL
preparations	NULL
.	NULL

To	NULL
maintain	NULL
equivalent	NULL
total	NULL
amounts	NULL
of	NULL
DNA	NULL
in	NULL
each	NULL
transfection	NULL
assay	NULL
some	NULL
plates	NULL
were	NULL
supplemented	NULL
with	NULL
vector	NULL
plasmid	NULL
pGEM-7Zf+	NULL
(	NULL
Promega	NULL
,	NULL
Inc.	NULL
)	NULL
to	NULL
bring	NULL
the	NULL
total	NULL
amount	NULL
to	NULL
20	NULL
ug	NULL
plasmid	NULL
DNA	NULL
.	NULL

The	NULL
DNA-CaPO	NULL
,	NULL
precipitates	NULL
(	NULL
1	NULL
ml	NULL
)	NULL
were	NULL
added	NULL
to	NULL
each	NULL
plate	NULL
containing	NULL
2.5	NULL
ml	NULL
of	NULL
medium	NULL
in	NULL
10-cm	NULL
``	NULL
plates	NULL
.	NULL

Seven	NULL
h	NULL
after	NULL
transfections	NULL
were	NULL
performed	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
throughly	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
and	NULL
they	NULL
were	NULL
refed	NULL
with	NULL
normal	NULL
growth	NULL
medium	NULL
at	NULL
24	NULL
and	NULL
48	NULL
h	NULL
following	NULL
transfections	NULL
.	NULL

The	NULL
uptake	NULL
of	NULL
DNA	NULL
was	NULL
internally	NULL
standardized	NULL
by	NULL
adding	NULL
1	NULL
ug	NULL
of	NULL
control	NULL
vector	NULL
pSV-hGH	NULL
,	NULL
encoding	NULL
secreted	NULL
human	NULL
growth	NULL
hormone	NULL
directed	NULL
by	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
promoter	NULL
,	NULL
for	NULL
each	NULL
transfection	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
and	NULL
harvested	NULL
72	NULL
h	NULL
after	NULL
transfections	NULL
and	NULL
lysed	NULL
with	NULL
a	NULL
transfection	NULL
lysis	NULL
reagent	NULL
(	NULL
Promega	NULL
,	NULL
Inc.	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
recommendations	NULL
.	NULL

Protein	NULL
concentrations	NULL
were	NULL
quantitated	NULL
by	NULL
the	NULL
dye-binding	NULL
procedure	NULL
(	NULL
Bio-Rad	NULL
)	NULL
.	NULL

CAT	NULL
assays	NULL
were	NULL
performed	NULL
essentially	NULL
as	NULL
described	NULL
(	NULL
33	NULL
)	NULL
and	NULL
CAT	NULL
activities	NULL
were	NULL
determined	NULL
by	NULL
acetylation	NULL
of	NULL
radiolabeled	NULL
chloramphenicol	NULL
.	NULL

Acetylated	NULL
chloramphenicol	NULL
products	NULL
were	NULL
separated	NULL
by	NULL
thin	NULL
layer	NULL
chromatography	NULL
and	NULL
quantitated	NULL
by	NULL
a	NULL
PhosphorImager	NULL
(	NULL
Molecular	NULL
Dynamics	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

Semi-confluent	NULL
Saos	NULL
2	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
either	NULL
15	NULL
pg	NULL
of	NULL
expression	NULL
plasmid	NULL
pCMV/UDGa	NULL
or	NULL
pCMV/0	NULL
along	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
the	NULL
B-cell	NULL
surface	NULL
antigen	NULL
CD19	NULL
cDNA	NULL
(	NULL
85	NULL
)	NULL
expression	NULL
plasmid	NULL
,	NULL
ped	NULL
19-hcr	NULL
,	NULL
which	NULL
were	NULL
all	NULL
directed	NULL
by	NULL
the	NULL
CMV	NULL
early	NULL
gene	NULL
promoter	NULL
.	NULL

The	NULL
cotransfected	NULL
cells	NULL
were	NULL
cultured	NULL
for	NULL
48	NULL
h	NULL
in	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
at	NULL
37°C	NULL
.	NULL

Immunocyto-chemical	NULL
rosettes	NULL
were	NULL
formed	NULL
of	NULL
cells	NULL
transiently	NULL
expressing	NULL
the	NULL
B	NULL
cell-specific	NULL
CD19	NULL
cell	NULL
surface	NULL
antigen	NULL
using	NULL
an	NULL
anti-CD19	NULL
antibody	NULL
conjugated	NULL
to	NULL
a	NULL
magnetic	NULL
bead	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
(	NULL
Dynal	NULL
,	NULL
Inc.	NULL
,	NULL
Lake	NULL
Success	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

Cotransfected	NULL
Saos2	NULL
cells	NULL
were	NULL
enriched	NULL
for	NULL
the	NULL
CD19*	NULL
phenotype	NULL
using	NULL
the	NULL
magnetically	NULL
susceptable	NULL
beads	NULL
and	NULL
detached	NULL
from	NULL
the	NULL
beads	NULL
according	NULL
to	NULL
manufacturer	NULL
's	NULL
direc-tions	NULL
.	NULL

Cotransfected	NULL
Saos	NULL
2	NULL
cells	NULL
,	NULL
positively	NULL
selected	NULL
for	NULL
CD19	NULL
,	NULL
were	NULL
then	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometric	NULL
procedures	NULL
.	NULL

Generation	NULL
of	NULL
UDG-specific	NULL
Antibody-A	NULL
nucleotide	NULL
sequence	NULL
of	NULL
the	NULL
protein	NULL
coding	NULL
fragment	NULL
(	NULL
Thr®	NULL
'	NULL
to	NULL
e*	NULL
``	NULL
)	NULL
within	NULL
the	NULL
UDG	NULL
gene	NULL
product	NULL
was	NULL
generated	NULL
by	NULL
the	NULL
PCR	NULL
method	NULL
using	NULL
Vent	NULL
,	NULL
®	NULL
DNA	NULL
polymerase	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
,	NULL
Inc.	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
recommendations	NULL
from	NULL
a	NULL
previously	NULL
cloned	NULL
cDNA	NULL
template	NULL
provided	NULL
(	NULL
S.	NULL
Caradonna	NULL
,	NULL
UMDNJ	NULL
)	NULL
.	NULL

This	NULL
was	NULL
accomplished	NULL
using	NULL
synthetic	NULL
oligonucleotide	NULL
primers	NULL
B'-AAGGGAATTCACGGCGGAATCCCGCTGTAAGCTG-3	NULL
'	NULL
and	NULL
5-AAG-GGAATTCCTACGCCAGGAGGGAAGGGGAGTA-3	NULL
'	NULL
containing	NULL
EcoRI	NULL
adaptor	NULL
ends	NULL
.	NULL

The	NULL
PCR	NULL
product	NULL
generated	NULL
was	NULL
digested	NULL
with	NULL
EcoRI	NULL
and	NULL
gel	NULL
purified	NULL
using	NULL
a	NULL
GeneClean	NULL
``	NULL
*	NULL
``	NULL
II	NULL
kit	NULL
(	NULL
Biol01	NULL
,	NULL
Inc.	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

The	NULL
purified	NULL
DNA	NULL
fragment	NULL
was	NULL
cloned	NULL
into	NULL
the	NULL
bacterial	NULL
,	NULL
pMAL-p2	NULL
,	NULL
expression	NULL
vector	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
,	NULL
Inc.	NULL
)	NULL
at	NULL
the	NULL
EcoRI	NULL
site	NULL
using	NULL
T4	NULL
DNA	NULL
ligase	NULL
.	NULL

Ligated	NULL
DNA	NULL
products	NULL
were	NULL
used	NULL
to	NULL
transform	NULL
commercially	NULL
available	NULL
competent	NULL
bacteria	NULL
,	NULL
DHSa	NULL
(	NULL
Life	NULL
Tech-nologies	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

Several	NULL
colonies	NULL
were	NULL
screened	NULL
for	NULL
the	NULL
correctly	NULL
inserted	NULL
PCR	NULL
fragment	NULL
by	NULL
inducible	NULL
protein	NULL
expression	NULL
of	NULL
the	NULL
correct	NULL
MeZE/UDG	NULL
The	NULL
UDG	NULL
Gene	NULL
Product	NULL
Inhibits	NULL
E2F-1-mediated	NULL
Transcription	NULL
fusion	NULL
gene	NULL
product	NULL
.	NULL

Plasmids	NULL
containing	NULL
the	NULL
protein	NULL
coding	NULL
inserts	NULL
were	NULL
sequenced	NULL
using	NULL
Sequenase	NULL
II®	NULL
DNA	NULL
sequencing	NULL
kit	NULL
to	NULL
verify	NULL
correct	NULL
nucleotide	NULL
sequence	NULL
and	NULL
orientation	NULL
.	NULL

Expression	NULL
and	NULL
affinity	NULL
purification	NULL
of	NULL
the	NULL
recombinant	NULL
MBP	NULL
fusion	NULL
protein	NULL
,	NULL
extending	NULL
through	NULL
the	NULL
cyclin-like	NULL
domain	NULL
(	NULL
Thr®	NULL
'	NULL
to	NULL
e**	NULL
)	NULL
of	NULL
the	NULL
UDG	NULL
protein	NULL
,	NULL
were	NULL
both	NULL
essentially	NULL
performed	NULL
as	NULL
described	NULL
by	NULL
the	NULL
manufacturer	NULL
of	NULL
MaZE	NULL
protein	NULL
fusion	NULL
kit	NULL
purchased	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

One-hundred	NULL
ug	NULL
of	NULL
affinity-purified	NULL
fusion	NULL
protein	NULL
was	NULL
used	NULL
to	NULL
immunize	NULL
mice	NULL
over	NULL
a	NULL
period	NULL
of	NULL
12	NULL
weeks	NULL
for	NULL
the	NULL
production	NULL
of	NULL
monoclonal	NULL
antibodies	NULL
specific	NULL
for	NULL
the	NULL
detection	NULL
of	NULL
human	NULL
UDG	NULL
using	NULL
procedures	NULL
previously	NULL
described	NULL
(	NULL
Harlow	NULL
and	NULL
Lane	NULL
,	NULL
1989	NULL
)	NULL
.	NULL

Hybridomas	NULL
were	NULL
made	NULL
,	NULL
and	NULL
individual	NULL
clones	NULL
were	NULL
screened	NULL
for	NULL
the	NULL
production	NULL
of	NULL
anti-UDG	NULL
antibodies	NULL
using	NULL
the	NULL
uracil-DNA	NULL
glycosylase	NULL
antigen	NULL
derived	NULL
from	NULL
an	NULL
in	NULL
vitro	NULL
translation	NULL
product	NULL
using	NULL
the	NULL
TNT®-coupled	NULL
reticulocyte	NULL
lysate	NULL
kit	NULL
purchased	NULL
(	NULL
Promega	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

Specific	NULL
mRNA	NULL
transcripts	NULL
were	NULL
generated	NULL
from	NULL
a	NULL
cDNA	NULL
template	NULL
of	NULL
UDG	NULL
previously	NULL
obtained	NULL
.	NULL

Monoclonal	NULL
antibody	NULL
mAb-u	NULL
(	NULL
91-243	NULL
)	NULL
was	NULL
obtained	NULL
from	NULL
a	NULL
hybridoma	NULL
clone	NULL
and	NULL
IgG	NULL
purified	NULL
by	NULL
affinity	NULL
chromatography	NULL
.	NULL

Immunoblotting-Using	NULL
approximately	NULL
2	NULL
x	NULL
10°	NULL
Saos	NULL
2	NULL
(	NULL
CD19*	NULL
phe-notype	NULL
)	NULL
cells	NULL
,	NULL
cotransfected	NULL
with	NULL
either	NULL
pCMV/UDGa	NULL
or	NULL
control	NULL
pCMV/0	NULL
,	NULL
cellular	NULL
lysates	NULL
were	NULL
prepared	NULL
by	NULL
sonication	NULL
at	NULL
4	NULL
°C	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
NETN	NULL
(	NULL
0.5	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
1	NULL
mm	NULL
EDTA	NULL
,	NULL
50	NULL
mm	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
8.0	NULL
,	NULL
120	NULL
mm	NULL
NaCl	NULL
)	NULL
containing	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
10	NULL
mM	NULL
NaF	NULL
,	NULL
2	NULL
mm	NULL
of	NULL
sodium	NULL
orthovanadate	NULL
,	NULL
1	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
,	NULL
and	NULL
10	NULL
pg/ml	NULL
each	NULL
of	NULL
aprotinin	NULL
,	NULL
leupeptin	NULL
,	NULL
TLCK	NULL
,	NULL
and	NULL
TPCK	NULL
prepared	NULL
from	NULL
fresh	NULL
stocks	NULL
.	NULL

Lysates	NULL
were	NULL
cleared	NULL
of	NULL
debris	NULL
by	NULL
microcentrifugation	NULL
(	NULL
14,000	NULL
x	NULL
g	NULL
)	NULL
at	NULL
4	NULL
°C	NULL
for	NULL
15	NULL
min	NULL
,	NULL
and	NULL
proteins	NULL
were	NULL
quantitated	NULL
by	NULL
the	NULL
Bradford	NULL
assay	NULL
using	NULL
a	NULL
commercial	NULL
kit	NULL
purchased	NULL
(	NULL
Bio-Rad	NULL
)	NULL
.	NULL

Twenty-five	NULL
ug	NULL
of	NULL
protein	NULL
sample	NULL
were	NULL
prepared	NULL
in	NULL
SDS-sample	NULL
buffer	NULL
and	NULL
fractionated	NULL
by	NULL
8.5	NULL
%	NULL
PAGE	NULL
under	NULL
denaturing	NULL
conditions	NULL
.	NULL

The	NULL
polyacrylamide	NULL
gel	NULL
was	NULL
electrophoresed	NULL
for	NULL
approximately	NULL
4	NULL
h	NULL
under	NULL
constant	NULL
voltage	NULL
(	NULL
150	NULL
V	NULL
)	NULL
in	NULL
running	NULL
buffer	NULL
containing	NULL
25	NULL
mM	NULL
Tris	NULL
,	NULL
pH	NULL
8.3	NULL
,	NULL
192	NULL
mm	NULL
glycine	NULL
,	NULL
and	NULL
0.1	NULL
%	NULL
SDS	NULL
.	NULL

Proteins	NULL
resolved	NULL
by	NULL
PAGE	NULL
were	NULL
electrophoreti-cally	NULL
transferred	NULL
to	NULL
polyvinlyidene	NULL
difluoride	NULL
membranes	NULL
(	NULL
Westran	NULL
``	NULL
``	NULL
,	NULL
Schleicher	NULL
&	NULL
Schuell	NULL
,	NULL
Inc.	NULL
)	NULL
in	NULL
running	NULL
buffer	NULL
under	NULL
constant	NULL
current	NULL
(	NULL
200	NULL
mA	NULL
)	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

Blocking	NULL
of	NULL
nonspecific	NULL
binding	NULL
by	NULL
the	NULL
primary	NULL
antibody	NULL
was	NULL
performed	NULL
with	NULL
5	NULL
%	NULL
non-fat	NULL
dry	NULL
milk	NULL
in	NULL
1	NULL
x	NULL
phosphate-buffered	NULL
saline	NULL
.	NULL

Immunoblotting	NULL
with	NULL
the	NULL
monoclonal	NULL
antibody	NULL
mAb-u	NULL
(	NULL
91-243	NULL
)	NULL
diluted	NULL
1:1000	NULL
was	NULL
accomplished	NULL
using	NULL
the	NULL
ECL	NULL
chemiluminescence	NULL
reagent	NULL
system	NULL
(	NULL
Amersham	NULL
Corp.	NULL
)	NULL
according	NULL
to	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

Immunoblot	NULL
was	NULL
exposed	NULL
to	NULL
film	NULL
XARS	NULL
for	NULL
10	NULL
s	NULL
and	NULL
developed	NULL
.	NULL

Flow	NULL
Cytofluorimetry-Saos	NULL
2	NULL
cultures	NULL
transfected	NULL
with	NULL
either	NULL
pCMV/UDGa	NULL
or	NULL
pCMV/O	NULL
identical	NULL
to	NULL
those	NULL
cultures	NULL
described	NULL
above	NULL
were	NULL
used	NULL
in	NULL
flow	NULL
cytofluorimetry	NULL
.	NULL

Flow	NULL
cytofluorimetry	NULL
was	NULL
performed	NULL
essentially	NULL
as	NULL
described	NULL
(	NULL
36	NULL
)	NULL
using	NULL
CD19*	NULL
population	NULL
of	NULL
Saos	NULL
2	NULL
cells	NULL
cotransfected	NULL
with	NULL
either	NULL
pCMV/UDGa	NULL
or	NULL
pCMV/0	NULL
.	NULL

Cell	NULL
cultures	NULL
were	NULL
taken	NULL
at	NULL
36	NULL
,	NULL
48	NULL
,	NULL
72	NULL
,	NULL
and	NULL
96	NULL
h	NULL
,	NULL
respectively	NULL
,	NULL
after	NULL
each	NULL
cotransfection	NULL
and	NULL
were	NULL
treated	NULL
with	NULL
5-bromo-2'-deoxyuridine	NULL
(	NULL
BrdUrd	NULL
)	NULL
for	NULL
60	NULL
min	NULL
and	NULL
nuclei	NULL
were	NULL
then	NULL
isolated	NULL
.	NULL

Isolated	NULL
nuclei	NULL
were	NULL
incubated	NULL
with	NULL
fluoros-cein-conjugated	NULL
IgG	NULL
antibody	NULL
,	NULL
specific	NULL
for	NULL
BrdU	NULL
incorporation	NULL
(	NULL
Becton-Dickinson	NULL
,	NULL
Inc.	NULL
)	NULL
,	NULL
for	NULL
1	NULL
h	NULL
at	NULL
4°C	NULL
.	NULL

Propidium	NULL
iodide	NULL
was	NULL
subsequently	NULL
added	NULL
to	NULL
the	NULL
nuclei	NULL
and	NULL
incubated	NULL
.	NULL

Both	NULL
BrdUrd	NULL
incorporation	NULL
and	NULL
propidium	NULL
iodide	NULL
fluorescence	NULL
were	NULL
analyzed	NULL
to	NULL
measure	NULL
,	NULL
respectively	NULL
,	NULL
DNA	NULL
synthesis	NULL
and	NULL
DNA	NULL
content/nucleus	NULL
in	NULL
a	NULL
FACScan	NULL
``	NULL
(	NULL
Becton-Dickinson	NULL
,	NULL
Inc.	NULL
)	NULL
using	NULL
the	NULL
Lysis	NULL
II	NULL
``	NULL
(	NULL
Hewlett-Packard	NULL
,	NULL
Inc.	NULL
)	NULL
software	NULL
program	NULL
to	NULL
analyze	NULL
data	NULL
.	NULL

[	NULL
°H	NULL
]	NULL
Thymidine	NULL
incorporation	NULL
studies	NULL
were	NULL
performed	NULL
on	NULL
parallel	NULL
Saos	NULL
2	NULL
cell	NULL
cultures	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
37	NULL
)	NULL
.	NULL

Bacterial	NULL
Expression	NULL
and	NULL
Purification	NULL
of	NULL
E2F-1	NULL
and	NULL
DP1-Glutathi-one	NULL
S-transferase	NULL
(	NULL
GST	NULL
)	NULL
bacterial	NULL
expression	NULL
plasmid	NULL
pGEX2TK-E2F-1	NULL
containing	NULL
the	NULL
E2F-1	NULL
cDNA	NULL
to	NULL
produce	NULL
a	NULL
bacterially	NULL
expressed	NULL
recombinant	NULL
GST/E2F-1	NULL
fusion	NULL
protein	NULL
was	NULL
a	NULL
kindly	NULL
provided	NULL
by	NULL
William	NULL
Kaelin	NULL
(	NULL
Dana	NULL
Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

Bacterial	NULL
strain	NULL
BL-21	NULL
was	NULL
transformed	NULL
with	NULL
the	NULL
pGEX2TK-E2F-1	NULL
,	NULL
cultured	NULL
in	NULL
Luria	NULL
broth	NULL
(	NULL
L-broth	NULL
)	NULL
,	NULL
and	NULL
induced	NULL
with	NULL
0.4	NULL
mM	NULL
ranoside	NULL
.	NULL

Lysates	NULL
of	NULL
the	NULL
transformed	NULL
bacteria	NULL
were	NULL
generated	NULL
by	NULL
sonication	NULL
in	NULL
a	NULL
suspension	NULL
buffer	NULL
containing	NULL
25	NULL
mm	NULL
HEPES	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
60	NULL
mm	NULL
KCl	NULL
,	NULL
5	NULL
mm	NULL
MgCl	NULL
,	NULL
,	NULL
1	NULL
mm	NULL
DTT	NULL
,	NULL
0.5	NULL
mM	NULL
spermidine	NULL
,	NULL
0.1	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
,	NULL
and	NULL
a	NULL
mixture	NULL
of	NULL
protease	NULL
inhibitors	NULL
(	NULL
0.1	NULL
ug	NULL
each	NULL
of	NULL
antipain	NULL
,	NULL
leupeptin	NULL
,	NULL
and	NULL
pepstatin	NULL
,	NULL
2	NULL
uM	NULL
each	NULL
TLCK	NULL
and	NULL
TPCK	NULL
)	NULL
,	NULL
added	NULL
immediately	NULL
prior	NULL
to	NULL
preparation	NULL
of	NULL
lysates	NULL
.	NULL

Glutathione	NULL
affinity	NULL
chromatography	NULL
of	NULL
fusion	NULL
protein	NULL
GST/E2F-1	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
23	NULL
)	NULL
.	NULL

The	NULL
DP1	NULL
cDNA	NULL
was	NULL
generously	NULL
provided	NULL
by	NULL
Rowena	NULL
Girling	NULL
and	NULL
Nicholas	NULL
La	NULL
Thangue	NULL
(	NULL
Medical	NULL
Research	NULL
Council	NULL
,	NULL
London	NULL
,	NULL
United	NULL
Kingdom	NULL
)	NULL
.	NULL

The	NULL
DP1	NULL
cDNA	NULL
fragment	NULL
,	NULL
necessary	NULL
to	NULL
generate	NULL
a	NULL
DP1	NULL
fusion	NULL
with	NULL
the	NULL
maltose-binding	NULL
protein	NULL
MBP	NULL
(	NULL
malFE	NULL
)	NULL
gene	NULL
,	NULL
was	NULL
synthesized	NULL
by	NULL
PCR	NULL
with	NULL
appropriate	NULL
adaptor	NULL
sequences	NULL
and	NULL
subcloned	NULL
into	NULL
pMAL-c2	NULL
vector	NULL
in	NULL
frame	NULL
with	NULL
the	NULL
malE	NULL
gene	NULL
.	NULL

The	NULL
expression	NULL
and	NULL
affinity	NULL
purification	NULL
of	NULL
the	NULL
DP1	NULL
fusion	NULL
gene	NULL
product	NULL
was	NULL
performed	NULL
5291	NULL
according	NULL
to	NULL
directions	NULL
recommended	NULL
by	NULL
the	NULL
manufacturer	NULL
of	NULL
pMAL-c2	NULL
.	NULL

Affinity-purified	NULL
gene	NULL
products	NULL
of	NULL
E2F-1	NULL
and	NULL
DP1	NULL
were	NULL
then	NULL
dialyzed	NULL
in	NULL
1000	NULL
volumes	NULL
of	NULL
DNA	NULL
binding	NULL
buffer	NULL
(	NULL
25	NULL
mm	NULL
HEPES	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
40	NULL
mx	NULL
KCl	NULL
,	NULL
1	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
glycerol	NULL
,	NULL
5	NULL
mm	NULL
MgCl	NULL
,	NULL
,	NULL
1	NULL
mm	NULL
DTT	NULL
)	NULL
and	NULL
analyzed	NULL
by	NULL
SDS-PAGE	NULL
prior	NULL
to	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
.	NULL

EMSA-All	NULL
oligonucleotide	NULL
DNA	NULL
fragments	NULL
were	NULL
synthesized	NULL
with	NULL
a	NULL
DNA	NULL
synthesizer	NULL
(	NULL
Applied	NULL
Biosystems	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

Complimentary	NULL
double-stranded	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
the	NULL
wild	NULL
type	NULL
UDG	NULL
promoter	NULL
sequence	NULL
expressed	NULL
as	NULL
UDG	NULL
construct-D/wt	NULL
and	NULL
mutated	NULL
sequences	NULL
characterized	NULL
by	NULL
UDG	NULL
construct-D/mut	NULL
were	NULL
synthesized	NULL
and	NULL
designated	NULL
as	NULL
oligonucleotide	NULL
UDG/wt1l	NULL
(	NULL
5'-GGTAGAGAGAAAATTCGC-GAAAGCTTTCCCGGTTGAGTC-3	NULL
'	NULL
)	NULL
and	NULL
UDG/M3	NULL
(	NULL
5-GGTAGAGAG-AAAATTCGCGAGAGC	NULL
GCTCCCGGTTGAGTC-3	NULL
'	NULL
)	NULL
,	NULL
respectively	NULL
,	NULL
were	NULL
used	NULL
in	NULL
the	NULL
EMSA	NULL
experiments	NULL
.	NULL

Oligonucleotides	NULL
were	NULL
5'-end-labeled	NULL
with	NULL
T	NULL
,	NULL
polynucleotide	NULL
kinase	NULL
and	NULL
[	NULL
y-*°P	NULL
]	NULL
JATP	NULL
and	NULL
then	NULL
annealed	NULL
.	NULL

EMSA	NULL
reactions	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
by	NULL
this	NULL
laboratory	NULL
(	NULL
37	NULL
)	NULL
.	NULL

Binding	NULL
reactions	NULL
were	NULL
carried	NULL
out	NULL
with	NULL
nuclear	NULL
extract	NULL
from	NULL
Saos	NULL
2	NULL
cells	NULL
or	NULL
with	NULL
25	NULL
ng	NULL
each	NULL
of	NULL
purified	NULL
E2F-1	NULL
and	NULL
DP1	NULL
in	NULL
a	NULL
17-ul	NULL
preincubation	NULL
mixture	NULL
with	NULL
DNA	NULL
binding	NULL
buffer	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4	NULL
°C	NULL
.	NULL

Then	NULL
the	NULL
*°P-labeled	NULL
oligonucleotides	NULL
were	NULL
added	NULL
and	NULL
incubated	NULL
for	NULL
an	NULL
additional	NULL
30	NULL
min	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
2	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
in	NULL
DNA	NULL
binding	NULL
buffer	NULL
.	NULL

Gel	NULL
electrophoresis	NULL
was	NULL
performed	NULL
on	NULL
a	NULL
4	NULL
%	NULL
polyacrylamide	NULL
(	NULL
80:1	NULL
acrylamide/bis-acrylamide	NULL
mixture	NULL
)	NULL
gel	NULL
in	NULL
a	NULL
Tris	NULL
acetate	NULL
buffer	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
37	NULL
)	NULL
.	NULL

For	NULL
competition	NULL
analysis	NULL
with	NULL
the	NULL
mutant	NULL
UDG	NULL
promoter	NULL
E2F	NULL
consensus	NULL
oligonucleotide	NULL
and	NULL
adenovirus	NULL
E2F	NULL
targets	NULL
,	NULL
a	NULL
100-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
competitor	NULL
(	NULL
relative	NULL
to	NULL
the	NULL
°°P-labeled	NULL
oligonucleotide	NULL
)	NULL
was	NULL
added	NULL
prior	NULL
to	NULL
the	NULL
binding	NULL
reaction	NULL
with	NULL
the	NULL
wild	NULL
type	NULL
*°P-labeled	NULL
oligonucleotide	NULL
.	NULL

RESULTS	NULL
E2F-1	NULL
Targets	NULL
the	NULL
Transactivation	NULL
of	NULL
the	NULL
Human	NULL
Nuclear	NULL
UDG	NULL
Gene	NULL
Promoter-Independent	NULL
cloning	NULL
of	NULL
the	NULL
human	NULL
UDG	NULL
promoter	NULL
from	NULL
previously	NULL
published	NULL
sequences	NULL
(	NULL
4	NULL
)	NULL
have	NULL
allowed	NULL
us	NULL
to	NULL
reexamine	NULL
the	NULL
sequence	NULL
of	NULL
the	NULL
UDG	NULL
promoter	NULL
,	NULL
which	NULL
reveals	NULL
several	NULL
potential	NULL
targets	NULL
for	NULL
EZF	NULL
activity	NULL
.	NULL

In	NULL
our	NULL
attempt	NULL
to	NULL
determine	NULL
if	NULL
this	NULL
UDG	NULL
gene	NULL
is	NULL
regulated	NULL
by	NULL
E2F-1	NULL
,	NULL
cotransfection	NULL
experiments	NULL
were	NULL
conducted	NULL
using	NULL
the	NULL
UDG	NULL
promoter	NULL
as	NULL
a	NULL
target	NULL
for	NULL
E2F-1	NULL
.	NULL

Transient	NULL
expression	NULL
of	NULL
the	NULL
recombinant	NULL
E2F-1	NULL
protein	NULL
,	NULL
directed	NULL
by	NULL
the	NULL
cytomegalovirus	NULL
early	NULL
gene	NULL
promoter	NULL
,	NULL
allowed	NULL
us	NULL
to	NULL
test	NULL
the	NULL
expression	NULL
of	NULL
E2F-1	NULL
on	NULL
the	NULL
transcriptional	NULL
response	NULL
given	NULL
by	NULL
1390	NULL
base	NULL
pairs	NULL
of	NULL
the	NULL
5'-flanking	NULL
region	NULL
of	NULL
the	NULL
human	NULL
UDG	NULL
gene	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
transient	NULL
expression	NULL
of	NULL
E2F-1	NULL
can	NULL
stimulate	NULL
the	NULL
expression	NULL
of	NULL
CAT	NULL
activity	NULL
when	NULL
driven	NULL
by	NULL
the	NULL
UDG	NULL
promoter	NULL
.	NULL

Levels	NULL
of	NULL
CAT	NULL
activity	NULL
were	NULL
evaluated	NULL
by	NULL
phosphoimag-ing	NULL
and	NULL
quantitated	NULL
the	NULL
stimulation	NULL
of	NULL
approximately	NULL
7.8-fold	NULL
when	NULL
compared	NULL
to	NULL
the	NULL
CMV	NULL
control	NULL
vector	NULL
pCMV/0	NULL
,	NULL
lacking	NULL
any	NULL
cDNA	NULL
insert	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

To	NULL
identify	NULL
the	NULL
boundaries	NULL
of	NULL
E2F-1	NULL
activity	NULL
within	NULL
the	NULL
promoter	NULL
,	NULL
several	NULL
deletions	NULL
of	NULL
the	NULL
UDG	NULL
gene	NULL
promoter	NULL
were	NULL
constructed	NULL
as	NULL
reporter	NULL
minigenes	NULL
to	NULL
account	NULL
for	NULL
putative	NULL
E2F	NULL
and	NULL
Sp1	NULL
sites	NULL
.	NULL

5	NULL
deletions	NULL
,	NULL
designated	NULL
as	NULL
UDG	NULL
constructs-B	NULL
,	NULL
-C	NULL
,	NULL
-D/wt	NULL
,	NULL
-D/mut	NULL
,	NULL
and	NULL
-F	NULL
,	NULL
omitted	NULL
sites	NULL
specific	NULL
for	NULL
the	NULL
presumed	NULL
recognition	NULL
by	NULL
E2F	NULL
and	NULL
Sp1	NULL
transcription	NULL
factors	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

These	NULL
deletions	NULL
extend	NULL
from	NULL
the	NULL
5	NULL
side	NULL
of	NULL
transcriptional	NULL
initiation	NULL
.	NULL

UDG	NULL
construct-E	NULL
was	NULL
a	NULL
deletion	NULL
mutant	NULL
derived	NULL
from	NULL
UDG	NULL
construct	NULL
D/wt	NULL
,	NULL
extending	NULL
from	NULL
the	NULL
3	NULL
'	NULL
side	NULL
of	NULL
transcription	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Minigene	NULL
constructs	NULL
containing	NULL
deletions	NULL
generated	NULL
from	NULL
the	NULL
5	NULL
'	NULL
end	NULL
of	NULL
the	NULL
UDG	NULL
promoter	NULL
were	NULL
cotransfected	NULL
with	NULL
the	NULL
E2F-1	NULL
expression	NULL
vector	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Reporter	NULL
gene	NULL
expression	NULL
from	NULL
the	NULL
5	NULL
'	NULL
deletion	NULL
mutants	NULL
demonstrate	NULL
the	NULL
relative	NULL
stimulation	NULL
resulting	NULL
from	NULL
each	NULL
of	NULL
the	NULL
putative	NULL
E2F	NULL
and	NULL
Spl	NULL
sites	NULL
.	NULL

The	NULL
CAT	NULL
activities	NULL
were	NULL
measured	NULL
with	NULL
values	NULL
(	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
proportional	NULL
to	NULL
the	NULL
presence	NULL
of	NULL
putative	NULL
E2F	NULL
targets	NULL
extending	NULL
from	NULL
the	NULL
5	NULL
'	NULL
end	NULL
.	NULL

In	NULL
each	NULL
set	NULL
of	NULL
cotransfection	NULL
experiments	NULL
,	NULL
a	NULL
negative	NULL
control	NULL
was	NULL
performed	NULL
in	NULL
parallel	NULL
with	NULL
cotransfections	NULL
performed	NULL
with	NULL
the	NULL
E2F-1	NULL
expression	NULL
vector	NULL
pCMV/	NULL
E2F-1	NULL
.	NULL

Cotransfections	NULL
using	NULL
the	NULL
parental	NULL
negative	NULL
control	NULL
vector	NULL
pCMV/O	NULL
allowed	NULL
us	NULL
to	NULL
access	NULL
the	NULL
stimulation	NULL
by	NULL
E2F-1	NULL
.	NULL

The	NULL
stimulation	NULL
by	NULL
E2F-1	NULL
was	NULL
quantitated	NULL
relative	NULL
to	NULL
cotransfec-	NULL
5292	NULL
The	NULL
UDG	NULL
Gene	NULL
Product	NULL
Inhibits	NULL
E2F-1-mediated	NULL
Transcription	NULL
+1	NULL
=	NULL
imumdy	NULL
Exon	NULL
1	NULL
EF	NULL
EF	NULL
E2F	NULL
-	NULL
Spi	NULL
Sp1	NULL
_	NULL
E2F	NULL
CMC	NULL
+_	NULL
a	NULL
~	NULL
~	NULL
XT	NULL
UDG	NULL
Construct	NULL
:	NULL
A	NULL
~1389	NULL
+81	NULL
C	NULL
UDG	NULL
Construct	NULL
:	NULL
B	NULL
~908	NULL
+81	NULL
f	NULL
--	NULL
-	NULL
UDG	NULL
Construct	NULL
C	NULL
683	NULL
+81	NULL
--	NULL
-	NULL
IY	NULL
UDG	NULL
Construct	NULL
Div	NULL
}	NULL
~445	NULL
+81	NULL
Zg/ﬁ—ﬂ	NULL
UDG	NULL
Construct	NULL
E	NULL
~445	NULL
+16	NULL
~445	NULL
C	NULL
--	NULL
INCI	NULL
--	NULL
-	NULL
#	NULL
%	NULL
é	NULL
--	NULL
|	NULL
UDG	NULL
Construct	NULL
F	NULL
~89	NULL
+81	NULL
E2F/mut	NULL
+81	NULL
f	NULL
--	NULL
-	NULL
]	NULL
UDG	NULL
Construct	NULL
Dimut	NULL
s	NULL
'	NULL
_	NULL
'	NULL
it	NULL
}	NULL
i	NULL
t	NULL
E.	NULL
%	NULL
%	NULL
€	NULL
4	NULL
&	NULL
e	NULL
&	NULL
e	NULL
Go	NULL
s	NULL
&	NULL
g	NULL
Go	NULL
s	NULL
Co	NULL
s	NULL
Go	NULL
s	NULL
f	NULL
A	NULL
¢	NULL
3	NULL
A	NULL
-	NULL
a	NULL
L	NULL
_	NULL
L	NULL
]	NULL
l	NULL
]	NULL
L	NULL
]	NULL
L	NULL
$	NULL
1	NULL
L	NULL
]	NULL
L	NULL
]	NULL
Na	NULL
®	NULL
6	NULL
C	NULL
&	NULL
&	NULL
#	NULL
5	NULL
&	NULL
**	NULL
&	NULL
s®	NULL
3°	NULL
&	NULL
&	NULL
``	NULL
36	NULL
}	NULL
&	NULL
&	NULL
``	NULL
&	NULL
s	NULL
s	NULL
s	NULL
09°C	NULL
?	NULL

sP	NULL
s	NULL
$	NULL
06	NULL
,	NULL
Fic	NULL
.	NULL

1	NULL
.	NULL

Mapping	NULL
of	NULL
E2F-1-mediated	NULL
transcription	NULL
in	NULL
the	NULL
human	NULL
UDG	NULL
promoter	NULL
.	NULL

A	NULL
,	NULL
schematic	NULL
illustration	NULL
of	NULL
a	NULL
series	NULL
of	NULL
human	NULL
UDG	NULL
promoter	NULL
deletion	NULL
constructs	NULL
fused	NULL
to	NULL
the	NULL
CAT	NULL
reporter	NULL
gene	NULL
.	NULL

The	NULL
top	NULL
schematic	NULL
is	NULL
used	NULL
as	NULL
reference	NULL
to	NULL
indicate	NULL
the	NULL
position	NULL
of	NULL
the	NULL
primary	NULL
transcriptional	NULL
start	NULL
postion	NULL
(	NULL
4	NULL
)	NULL
and	NULL
first	NULL
exon	NULL
relative	NULL
to	NULL
the	NULL
promoter	NULL
construct	NULL
tested	NULL
.	NULL

Numbers	NULL
below	NULL
each	NULL
promoter/reporter	NULL
construct	NULL
denote	NULL
the	NULL
position	NULL
of	NULL
the	NULL
UDG	NULL
promoter	NULL
end	NULL
points	NULL
at	NULL
both	NULL
the	NULL
5	NULL
'	NULL
and	NULL
3	NULL
'	NULL
ends	NULL
,	NULL
respective	NULL
of	NULL
this	NULL
transcriptional	NULL
initiation	NULL
site	NULL
.	NULL

The	NULL
solid	NULL
boxes	NULL
indicate	NULL
the	NULL
postion	NULL
of	NULL
each	NULL
putative	NULL
E2F	NULL
consensus	NULL
site	NULL
,	NULL
and	NULL
hatched	NULL
boxes	NULL
represent	NULL
the	NULL
position	NULL
of	NULL
putative	NULL
Sp1	NULL
sites	NULL
within	NULL
the	NULL
promoter	NULL
region	NULL
.	NULL

Open	NULL
box	NULL
with	NULL
an	NULL
X	NULL
indicates	NULL
a	NULL
mutation	NULL
directed	NULL
within	NULL
an	NULL
E2F	NULL
consensus	NULL
site	NULL
.	NULL

B	NULL
,	NULL
transcriptional	NULL
effect	NULL
of	NULL
recombinant	NULL
E2F-1	NULL
on	NULL
wild	NULL
type	NULL
and	NULL
mutant	NULL
gene	NULL
promoter	NULL
constructs	NULL
.	NULL

Shown	NULL
is	NULL
an	NULL
assay	NULL
used	NULL
to	NULL
detect	NULL
chloramphenicol	NULL
acetyltransferase	NULL
activity	NULL
used	NULL
to	NULL
measure	NULL
transcriptional	NULL
activity	NULL
mediated	NULL
by	NULL
a	NULL
cotransfected	NULL
E2F-1	NULL
expression	NULL
vector	NULL
.	NULL

The	NULL
UDG	NULL
promoter	NULL
constructs	NULL
,	NULL
fused	NULL
to	NULL
the	NULL
CAT	NULL
reporter	NULL
gene	NULL
,	NULL
were	NULL
cotransfected	NULL
each	NULL
with	NULL
either	NULL
the	NULL
E2F-1	NULL
expression	NULL
vector	NULL
pCMV/E2F-1	NULL
or	NULL
negative	NULL
control	NULL
vector	NULL
pCMV/0	NULL
.	NULL

CAT	NULL
assays	NULL
were	NULL
performed	NULL
and	NULL
CAT	NULL
gene	NULL
activity	NULL
verified	NULL
by	NULL
an	NULL
autoradiograph	NULL
of	NULL
the	NULL
thin	NULL
layer	NULL
chromatograph	NULL
shown	NULL
.	NULL

tions	NULL
performed	NULL
with	NULL
pCMV/O	NULL
in	NULL
each	NULL
of	NULL
the	NULL
reporter	NULL
minigene	NULL
plasmids	NULL
shown	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Results	NULL
from	NULL
this	NULL
experiment	NULL
represent	NULL
the	NULL
level	NULL
at	NULL
which	NULL
E2F-1	NULL
can	NULL
transactivate	NULL
the	NULL
individual	NULL
minigene	NULL
reporter	NULL
constructs	NULL
.	NULL

Although	NULL
cotransfection	NULL
of	NULL
these	NULL
deletion	NULL
mutants	NULL
with	NULL
the	NULL
E2F-1	NULL
expression	NULL
vector	NULL
indicate	NULL
the	NULL
relative	NULL
contribution	NULL
of	NULL
these	NULL
sites	NULL
in	NULL
E2F-mediated	NULL
transactivation	NULL
of	NULL
the	NULL
UDG	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
,	NULL
the	NULL
basal	NULL
levels	NULL
of	NULL
CAT	NULL
activity	NULL
are	NULL
also	NULL
proportional	NULL
to	NULL
the	NULL
length	NULL
of	NULL
the	NULL
UDG	NULL
promoter	NULL
.	NULL

This	NULL
is	NULL
demonstrated	NULL
by	NULL
the	NULL
negative	NULL
control	NULL
expression	NULL
vector	NULL
pCMV/0	NULL
cotransfected	NULL
with	NULL
each	NULL
of	NULL
the	NULL
deletions	NULL
extending	NULL
from	NULL
the	NULL
5	NULL
end	NULL
.	NULL

Values	NULL
presented	NULL
as	NULL
histograms	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
,	NULL
indicating	NULL
the	NULL
relative	NULL
activity	NULL
of	NULL
each	NULL
minigene	NULL
construct	NULL
,	NULL
show	NULL
the	NULL
relative	NULL
contribution	NULL
of	NULL
each	NULL
E2F	NULL
site	NULL
to	NULL
E2F-1-mediated	NULL
stimulation	NULL
of	NULL
UDG	NULL
gene	NULL
transcription	NULL
.	NULL

Deletion	NULL
of	NULL
the	NULL
The	NULL
UDG	NULL
Gene	NULL
Product	NULL
Inhibits	NULL
E2F-1-mediated	NULL
Transcription	NULL
UDG	NULL
Construct-B	NULL
UDG	NULL
Construct-C	NULL
UDG	NULL
Construct-Diwt	NULL
UDG	NULL
Construct-E	NULL
UDG	NULL
Construct-F	NULL
UDG	NULL
Construct-D/mut	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
10	NULL
45	NULL
5293	NULL
J	NULL
L__1	NULL
6.3+1.8	NULL
|	NULL
1	NULL
7.5+1.2	NULL
_	NULL
I	NULL
0.8+0.2	NULL
_	NULL
U	NULL
22.7+3.4	NULL
_I	NULL
§§	NULL
or	NULL
:	NULL
«	NULL
Negative	NULL
control	NULL
2110.9	NULL
L	NULL
--	NULL
20	NULL
25	NULL
30	NULL
35	NULL
40	NULL
45	NULL
50	NULL
55	NULL
60	NULL
CAT	NULL
Activity	NULL
(	NULL
%	NULL
acetylation	NULL
)	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

Comparative	NULL
quantitation	NULL
of	NULL
E2F-1-mediated	NULL
induction	NULL
of	NULL
UDG	NULL
gene	NULL
transcription	NULL
.	NULL

The	NULL
histogram	NULL
evaluates	NULL
,	NULL
comparatively	NULL
,	NULL
the	NULL
levels	NULL
of	NULL
E2F-1	NULL
stimulation	NULL
of	NULL
transcription	NULL
mediated	NULL
by	NULL
each	NULL
of	NULL
the	NULL
promoter	NULL
constructs	NULL
tested	NULL
.	NULL

The	NULL
graph	NULL
represents	NULL
the	NULL
percent	NULL
conversion	NULL
to	NULL
an	NULL
acetylated	NULL
form	NULL
of	NULL
chloramphenicol	NULL
in	NULL
each	NULL
cotransfection	NULL
performed	NULL
with	NULL
either	NULL
pCMV/E2F-1	NULL
or	NULL
the	NULL
negative	NULL
control	NULL
pCMV/O	NULL
.	NULL

Numerical	NULL
values	NULL
,	NULL
adjacent	NULL
to	NULL
the	NULL
graph	NULL
,	NULL
indicate	NULL
the	NULL
degree	NULL
of	NULL
stimulation	NULL
mediated	NULL
by	NULL
the	NULL
transient	NULL
expression	NULL
of	NULL
E2F-1	NULL
when	NULL
compared	NULL
to	NULL
the	NULL
negative	NULL
control	NULL
signal	NULL
.	NULL

The	NULL
-fold	NULL
stimulation	NULL
of	NULL
reporter	NULL
gene	NULL
activity	NULL
was	NULL
calculated	NULL
by	NULL
the	NULL
amount	NULL
of	NULL
acetylation	NULL
(	NULL
percent	NULL
)	NULL
from	NULL
cells	NULL
transfected	NULL
with	NULL
pCMV/E2F-1	NULL
divided	NULL
by	NULL
the	NULL
amount	NULL
of	NULL
acetylation	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
negative	NULL
control	NULL
vector	NULL
pCMV/O	NULL
.	NULL

Internal	NULL
control	NULL
plasmid	NULL
directing	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
reporter	NULL
human	NULL
growth	NULL
hormone	NULL
was	NULL
included	NULL
to	NULL
standardize	NULL
transfection	NULL
efficiency	NULL
for	NULL
each	NULL
experiment	NULL
performed	NULL
.	NULL

The	NULL
+	NULL
indicates	NULL
the	NULL
standard	NULL
error	NULL
from	NULL
four	NULL
separate	NULL
transfection	NULL
experiments	NULL
performed	NULL
with	NULL
two	NULL
separate	NULL
preparations	NULL
of	NULL
plasmid	NULL
DNA	NULL
.	NULL

proximal	NULL
Sp1	NULL
site	NULL
reduces	NULL
the	NULL
activity	NULL
of	NULL
E2F-1-mediated	NULL
transcription	NULL
of	NULL
the	NULL
UDG	NULL
promoter	NULL
approximately	NULL
4-fold	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

It	NULL
is	NULL
therefore	NULL
consistent	NULL
with	NULL
other	NULL
genetic	NULL
models	NULL
indicating	NULL
the	NULL
importance	NULL
of	NULL
Spl	NULL
in	NULL
basal	NULL
stimulation	NULL
and	NULL
start	NULL
site	NULL
selection	NULL
of	NULL
gene	NULL
transcription	NULL
(	NULL
88	NULL
,	NULL
39	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
activity	NULL
of	NULL
this	NULL
Sp1	NULL
site	NULL
provides	NULL
some	NULL
evidence	NULL
that	NULL
Spl	NULL
may	NULL
synergistically	NULL
co-stimulate	NULL
E2F-1	NULL
transcriptional	NULL
activity	NULL
,	NULL
the	NULL
function	NULL
of	NULL
Spl	NULL
on	NULL
E2F-1	NULL
activity	NULL
is	NULL
likely	NULL
through	NULL
a	NULL
basal	NULL
mechanism	NULL
.	NULL

The	NULL
role	NULL
of	NULL
Spl	NULL
in	NULL
UDG	NULL
gene	NULL
transcription	NULL
remains	NULL
to	NULL
be	NULL
further	NULL
elucidated	NULL
.	NULL

Site-specific	NULL
mutation	NULL
of	NULL
the	NULL
UDG	NULL
promoter	NULL
within	NULL
the	NULL
core	NULL
downstream	NULL
of	NULL
the	NULL
putative	NULL
E2F	NULL
target	NULL
was	NULL
converted	NULL
from	NULL
the	NULL
wild	NULL
type	NULL
5-TTCGCGAAAGCTTTCCCGGTT-3	NULL
'	NULL
to	NULL
the	NULL
mutant	NULL
sequence	NULL
5'-TTCGCGAGAGCGCTCCCGGTT-3	NULL
'	NULL
.	NULL

The	NULL
strategy	NULL
for	NULL
site-directed	NULL
mutagenesis	NULL
was	NULL
developed	NULL
to	NULL
destroy	NULL
the	NULL
affinity	NULL
of	NULL
-specific	NULL
binding	NULL
to	NULL
the	NULL
UDG	NULL
promoter	NULL
at	NULL
the	NULL
most	NULL
proximal	NULL
E2F	NULL
site	NULL
relative	NULL
to	NULL
transcriptional	NULL
initiation	NULL
.	NULL

This	NULL
is	NULL
consistent	NULL
with	NULL
previous	NULL
experiments	NULL
that	NULL
examine	NULL
the	NULL
sequence-specific	NULL
affinity	NULL
of	NULL
DNA	NULL
binding	NULL
by	NULL
cellular	NULL
E2F	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Cotransfections	NULL
performed	NULL
with	NULL
pCMV/E2F-1	NULL
and	NULL
the	NULL
reporter	NULL
minigene	NULL
UDG	NULL
construct-D/mut	NULL
reduce	NULL
vitrually	NULL
all	NULL
of	NULL
the	NULL
stimulation	NULL
resulting	NULL
from	NULL
the	NULL
transient	NULL
expression	NULL
of	NULL
E2F-1	NULL
(	NULL
Figs	NULL
.	NULL

1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

The	NULL
site-specific	NULL
mutagenesis	NULL
of	NULL
the	NULL
UDG	NULL
human	NULL
promoter	NULL
accounts	NULL
for	NULL
the	NULL
majority	NULL
of	NULL
transactivation	NULL
provided	NULL
by	NULL
E2F-1	NULL
.	NULL

Although	NULL
these	NULL
results	NULL
do	NULL
not	NULL
completely	NULL
account	NULL
for	NULL
the	NULL
degenerated	NULL
consensus	NULL
of	NULL
E2F	NULL
binding	NULL
,	NULL
this	NULL
report	NULL
indicates	NULL
that	NULL
this	NULL
triple	NULL
mutation	NULL
within	NULL
the	NULL
E2F	NULL
core	NULL
element	NULL
is	NULL
sufficient	NULL
for	NULL
destroying	NULL
the	NULL
majority	NULL
of	NULL
E2F-1-mediated	NULL
transactivation	NULL
.	NULL

E2F	NULL
Recognizes	NULL
a	NULL
Cognate	NULL
Element	NULL
Located	NULL
Immediately	NULL
Downstream	NULL
of	NULL
UDG	NULL
Gene	NULL
Transcription-Nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
synchronized	NULL
Saos	NULL
2	NULL
cells	NULL
in	NULL
G1	NULL
were	NULL
used	NULL
in	NULL
a	NULL
band	NULL
mobility	NULL
shift	NULL
assay	NULL
to	NULL
biochemically	NULL
define	NULL
the	NULL
physical	NULL
interaction	NULL
between	NULL
E2F	NULL
and	NULL
the	NULL
UDG	NULL
gene	NULL
promoter	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
data	NULL
presented	NULL
in	NULL
Figs	NULL
.	NULL

1	NULL
and	NULL
2	NULL
demonstrating	NULL
the	NULL
transactivating	NULL
potential	NULL
of	NULL
EZF-1	NULL
,	NULL
we	NULL
see	NULL
one	NULL
specific	NULL
complex	NULL
of	NULL
the	NULL
UDG	NULL
promoter	NULL
element	NULL
extending	NULL
from	NULL
+7	NULL
to	NULL
+35	NULL
from	NULL
the	NULL
transcriptional	NULL
start	NULL
site	NULL
.	NULL

This	NULL
interaction	NULL
was	NULL
aggressively	NULL
competed	NULL
out	NULL
with	NULL
copious	NULL
amounts	NULL
of	NULL
unlabeled	NULL
specific	NULL
oligonucleotide	NULL
competitor	NULL
DNA	NULL
(	NULL
100-fold	NULL
)	NULL
,	NULL
corresponding	NULL
to	NULL
the	NULL
E2F	NULL
site	NULL
of	NULL
the	NULL
adenovirus	NULL
E2	NULL
promoter	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

34	NULL
.	NULL

This	NULL
suggests	NULL
the	NULL
direct	NULL
interaction	NULL
between	NULL
the	NULL
E2F-specific	NULL
complex	NULL
with	NULL
an	NULL
element	NULL
in	NULL
the	NULL
UDG	NULL
gene	NULL
promoter	NULL
associated	NULL
with	NULL
E2F-1-mediated	NULL
transactivation	NULL
.	NULL

Binding	NULL
to	NULL
the	NULL
Proximal	NULL
E2F	NULL
Target	NULL
Requires	NULL
Heterodimeric	NULL
Formation	NULL
between	NULL
E2F-1	NULL
and	NULL
DP1-A	NULL
direct	NULL
biochemical	NULL
approach	NULL
to	NULL
examine	NULL
the	NULL
association	NULL
between	NULL
E2F	NULL
and	NULL
the	NULL
UDG	NULL
promoter	NULL
is	NULL
to	NULL
test	NULL
the	NULL
physical	NULL
nature	NULL
of	NULL
the	NULL
interaction	NULL
between	NULL
E2F	NULL
and	NULL
a	NULL
potential	NULL
cognate	NULL
element	NULL
located	NULL
downstream	NULL
of	NULL
UDG	NULL
transcription	NULL
.	NULL

An	NULL
in	NULL
vitro	NULL
assay	NULL
to	NULL
distinguish	NULL
sequence-specific	NULL
DNA	NULL
binding	NULL
by	NULL
a	NULL
heterodimer	NULL
of	NULL
E2F	NULL
,	NULL
E2F-1	NULL
,	NULL
and	NULL
DP1	NULL
,	NULL
fusion	NULL
proteins	NULL
were	NULL
generated	NULL
from	NULL
bacterial	NULL
expression	NULL
vectors	NULL
.	NULL

Fusion	NULL
proteins	NULL
of	NULL
GST/E2F-1	NULL
and	NULL
MBP/	NULL
DP1	NULL
were	NULL
purified	NULL
by	NULL
affinity	NULL
chromatography	NULL
and	NULL
examined	NULL
by	NULL
SDS-PAGE	NULL
.	NULL

The	NULL
results	NULL
of	NULL
the	NULL
purification	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3B	NULL
.	NULL

It	NULL
had	NULL
been	NULL
previously	NULL
demonstrated	NULL
that	NULL
heterodimeriza-tion	NULL
between	NULL
two	NULL
partners	NULL
E2F-1	NULL
and	NULL
DP1	NULL
was	NULL
a	NULL
prerequiste	NULL
for	NULL
both	NULL
optimal	NULL
DNA	NULL
binding	NULL
and	NULL
transcriptional	NULL
activation	NULL
mediated	NULL
by	NULL
the	NULL
E2F	NULL
complex	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Using	NULL
a	NULL
°°P-labeled	NULL
oligonucleotide	NULL
,	NULL
corresponding	NULL
to	NULL
the	NULL
E2F	NULL
consensus	NULL
located	NULL
be	NULL
5294	NULL
The	NULL
UDG	NULL
Gene	NULL
Product	NULL
Inhibits	NULL
E2F-1-mediated	NULL
Transcription	NULL
®	NULL
competitor	NULL
$	NULL
64	NULL
?	NULL

ﬁx	NULL
l	NULL
malEDP1	NULL
-	NULL
$	NULL
-	NULL
o	NULL
$	NULL
$	NULL
%	NULL
4	NULL
DP1/E2F-1	NULL
-f	NULL
»	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

The	NULL
E2F	NULL
complex	NULL
recognizes	NULL
an	NULL
E2F	NULL
consensus	NULL
within	NULL
the	NULL
human	NULL
UDG	NULL
promoter	NULL
.	NULL

A	NULL
putative	NULL
E2F	NULL
site	NULL
,	NULL
located	NULL
immediately	NULL
downstream	NULL
of	NULL
transcription	NULL
,	NULL
requires	NULL
the	NULL
heterodimer	NULL
of	NULL
E2F-1	NULL
and	NULL
DP1	NULL
for	NULL
efficient	NULL
DNA	NULL
binding	NULL
.	NULL

A	NULL
,	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
Saos	NULL
2	NULL
cells	NULL
,	NULL
synchronized	NULL
in	NULL
G	NULL
,	NULL
,	NULL
were	NULL
used	NULL
in	NULL
an	NULL
EMSA	NULL
experiment	NULL
to	NULL
detect	NULL
a	NULL
specific	NULL
DNA-E2F	NULL
complex	NULL
.	NULL

A	NULL
double-stranded	NULL
oligonucleotide	NULL
probe	NULL
,	NULL
corresponding	NULL
to	NULL
the	NULL
region	NULL
of	NULL
the	NULL
UDG	NULL
promoter	NULL
between	NULL
+7	NULL
to	NULL
+35	NULL
,	NULL
was	NULL
labeled	NULL
with	NULL
*°P	NULL
and	NULL
incubated	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
nuclear	NULL
extract	NULL
.	NULL

All	NULL
binding	NULL
reactions	NULL
were	NULL
preincubated	NULL
with	NULL
nonspecific	NULL
competitor	NULL
DNA	NULL
(	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
)	NULL
.	NULL

Gel	NULL
shift	NULL
analysis	NULL
was	NULL
also	NULL
performed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
specific	NULL
competitor	NULL
DNA	NULL
corresponding	NULL
to	NULL
the	NULL
E2F	NULL
recognition	NULL
site	NULL
of	NULL
the	NULL
adenovirus	NULL
E2	NULL
promoter	NULL
(	NULL
shown	NULL
in	NULL
the	NULL
last	NULL
lane	NULL
)	NULL
.	NULL

Prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
*°P-labeled	NULL
oligonucleotide	NULL
,	NULL
the	NULL
E2F	NULL
competitor	NULL
sequence	NULL
from	NULL
the	NULL
adenovirus	NULL
E2	NULL
promoter	NULL
was	NULL
added	NULL
to	NULL
the	NULL
nuclear	NULL
extract	NULL
in	NULL
100-fold	NULL
excess	NULL
(	NULL
relative	NULL
to	NULL
the	NULL
labeled	NULL
oligonucleotide	NULL
probe	NULL
)	NULL
and	NULL
assayed	NULL
by	NULL
band	NULL
mobility	NULL
shift	NULL
analysis	NULL
.	NULL

B	NULL
,	NULL
SDS-PAGE	NULL
,	NULL
following	NULL
the	NULL
affinity	NULL
purification	NULL
of	NULL
bacterially	NULL
generated	NULL
malE/DP1	NULL
and	NULL
GST/E2F-1	NULL
fusion	NULL
proteins	NULL
,	NULL
was	NULL
stained	NULL
with	NULL
Coomassie	NULL
Blue	NULL
stain	NULL
and	NULL
photographed	NULL
.	NULL

Molecular	NULL
mass	NULL
markers	NULL
adjacent	NULL
to	NULL
samples	NULL
are	NULL
indicated	NULL
in	NULL
kilodaltons	NULL
.	NULL

C	NULL
,	NULL
EMSA	NULL
of	NULL
bacterially	NULL
produced	NULL
and	NULL
affinity-purified	NULL
E2F-1	NULL
and	NULL
DP1	NULL
fusion	NULL
gene	NULL
products	NULL
,	NULL
individually	NULL
and	NULL
together	NULL
,	NULL
were	NULL
used	NULL
to	NULL
analyze	NULL
DNA	NULL
binding	NULL
to	NULL
the	NULL
wild	NULL
type	NULL
and	NULL
mutant	NULL
E2F	NULL
consensus	NULL
elements	NULL
from	NULL
the	NULL
UDG	NULL
promoter	NULL
(	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
``	NULL
)	NULL
.	NULL

Oligonucleotide	NULL
competitor	NULL
DNA	NULL
,	NULL
corresponding	NULL
to	NULL
the	NULL
E2F	NULL
target	NULL
of	NULL
the	NULL
adenovirus	NULL
E2	NULL
gene	NULL
promoter	NULL
was	NULL
used	NULL
in	NULL
the	NULL
last	NULL
lane	NULL
.	NULL

tween	NULL
+7	NULL
and	NULL
+35	NULL
,	NULL
we	NULL
performed	NULL
band	NULL
mobility	NULL
shift	NULL
assays	NULL
.	NULL

Results	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3C	NULL
demonstrate	NULL
the	NULL
interaction	NULL
of	NULL
the	NULL
bacterially	NULL
generated	NULL
E2F-1	NULL
and	NULL
DP1	NULL
heterodimers	NULL
with	NULL
the	NULL
oligonucleotide	NULL
sequence	NULL
is	NULL
readily	NULL
apparent	NULL
by	NULL
the	NULL
mobility	NULL
shift	NULL
as	NULL
a	NULL
single	NULL
DNA-protein	NULL
complex	NULL
.	NULL

But	NULL
neither	NULL
E2F-1	NULL
or	NULL
DP1	NULL
,	NULL
individually	NULL
,	NULL
can	NULL
bind	NULL
this	NULL
DNA	NULL
element	NULL
effectively	NULL
.	NULL

To	NULL
ensure	NULL
the	NULL
sequence	NULL
specificity	NULL
of	NULL
the	NULL
DNA-protein	NULL
interactions	NULL
E2F-specific	NULL
,	NULL
competitor	NULL
DNA	NULL
from	NULL
the	NULL
adenovirus	NULL
E2	NULL
promoter	NULL
was	NULL
tested	NULL
and	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
to	NULL
compete	NULL
for	NULL
DNA	NULL
binding	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
competition	NULL
analysis	NULL
with	NULL
the	NULL
mutant	NULL
oligonucleotide	NULL
UDG-M3	NULL
(	NULL
characteristic	NULL
of	NULL
the	NULL
reporter	NULL
minigene	NULL
tested	NULL
,	NULL
UDG	NULL
construct-D/mut	NULL
)	NULL
competed	NULL
only	NULL
slightly	NULL
for	NULL
the	NULL
affinity	NULL
of	NULL
the	NULL
E2F-1/DP1	NULL
heterodimer	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
.	NULL

Although	NULL
DNA	NULL
binding	NULL
by	NULL
the	NULL
E2F-1/DP1	NULL
heterodimer	NULL
to	NULL
the	NULL
imperfect	NULL
inverted	NULL
repeat	NULL
sequence	NULL
of	NULL
5'-CGCGAAAGCTTTCCCGG-3	NULL
'	NULL
is	NULL
somewhat	NULL
analogous	NULL
to	NULL
the	NULL
inverted	NULL
double	NULL
site	NULL
found	NULL
in	NULL
the	NULL
adenovirus	NULL
E2	NULL
(	NULL
40	NULL
)	NULL
or	NULL
dihydrofolate	NULL
reductase	NULL
gene	NULL
promoters	NULL
(	NULL
7	NULL
)	NULL
,	NULL
we	NULL
have	NULL
not	NULL
yet	NULL
determined	NULL
if	NULL
this	NULL
specific	NULL
E2F	NULL
consensus	NULL
sequence	NULL
can	NULL
provide	NULL
the	NULL
level	NULL
of	NULL
E2F-mediated	NULL
transcription	NULL
or	NULL
DNA	NULL
binding	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
other	NULL
heterologous	NULL
E2F-responsive	NULL
gene	NULL
promoters	NULL
.	NULL

A	NULL
mutation	NULL
to	NULL
the	NULL
core	NULL
of	NULL
the	NULL
E2F	NULL
consensus	NULL
sequence	NULL
in	NULL
the	NULL
UDG	NULL
promoter	NULL
reflects	NULL
the	NULL
requirement	NULL
for	NULL
the	NULL
precise	NULL
E2F	NULL
consensus	NULL
for	NULL
E2F-1-mediated	NULL
transactivation	NULL
(	NULL
Figs	NULL
.	NULL

1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

Failure	NULL
of	NULL
the	NULL
mutated	NULL
E2F	NULL
target	NULL
(	NULL
UDG-M3	NULL
)	NULL
to	NULL
readily	NULL
compete	NULL
for	NULL
binding	NULL
by	NULL
the	NULL
E2F-1/DP1	NULL
heterodimer	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
is	NULL
consistent	NULL
with	NULL
other	NULL
examples	NULL
of	NULL
E2F-mediated	NULL
DNA	NULL
binding	NULL
and	NULL
transcriptional	NULL
activation	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Overexpression	NULL
of	NULL
UDG	NULL
Delays	NULL
Growth	NULL
Late	NULL
in	NULL
G	NULL
,	NULL
-As	NULL
a	NULL
component	NULL
of	NULL
this	NULL
study	NULL
to	NULL
determine	NULL
the	NULL
effect	NULL
of	NULL
overexpression	NULL
of	NULL
recombinant	NULL
UDG	NULL
on	NULL
E2F-1-mediated	NULL
expression	NULL
,	NULL
we	NULL
first	NULL
examined	NULL
the	NULL
physiological	NULL
status	NULL
of	NULL
Saos	NULL
2	NULL
cells	NULL
expressing	NULL
constitutively	NULL
high	NULL
levels	NULL
of	NULL
UDG	NULL
.	NULL

Because	NULL
of	NULL
the	NULL
relative	NULL
homology	NULL
to	NULL
a	NULL
class	NULL
of	NULL
cyclin	NULL
proteins	NULL
,	NULL
we	NULL
have	NULL
suspected	NULL
UDG	NULL
of	NULL
participating	NULL
in	NULL
cellular	NULL
events	NULL
possibly	NULL
analogous	NULL
to	NULL
that	NULL
of	NULL
some	NULL
cyclin	NULL
proteins	NULL
as	NULL
described	NULL
(	NULL
42	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
indicated	NULL
that	NULL
the	NULL
A-type	NULL
cyclin	NULL
nuclear	NULL
protein	NULL
perform	NULL
specialized	NULL
functions	NULL
required	NULL
for	NULL
the	NULL
onset	NULL
and	NULL
maintenance	NULL
of	NULL
the	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
(	NULL
43	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
as	NULL
a	NULL
way	NULL
of	NULL
analyzing	NULL
the	NULL
activity	NULL
of	NULL
constitutive	NULL
and	NULL
abundant	NULL
expression	NULL
of	NULL
UDG	NULL
,	NULL
we	NULL
quantitated	NULL
the	NULL
relative	NULL
cell	NULL
populations	NULL
at	NULL
G/G	NULL
,	NULL
S	NULL
,	NULL
and	NULL
Gy/M	NULL
expressing	NULL
a	NULL
CD19	NULL
cell	NULL
surface	NULL
marker	NULL
.	NULL

Expression	NULL
of	NULL
UDG	NULL
,	NULL
directed	NULL
by	NULL
the	NULL
CMV	NULL
early	NULL
gene	NULL
promoter	NULL
,	NULL
reveals	NULL
abundant	NULL
levels	NULL
of	NULL
UDG	NULL
expression	NULL
when	NULL
compared	NULL
to	NULL
that	NULL
of	NULL
the	NULL
negative	NULL
expression	NULL
vector	NULL
control	NULL
.	NULL

Cell	NULL
cultures	NULL
removed	NULL
at	NULL
48	NULL
h	NULL
following	NULL
cotransfections	NULL
performed	NULL
with	NULL
pCMV/UDGa	NULL
or	NULL
pCMV/O	NULL
along	NULL
with	NULL
the	NULL
CD19	NULL
expression	NULL
vector	NULL
,	NULL
as	NULL
shown	NULL
by	NULL
an	NULL
immunoblot	NULL
experiment	NULL
,	NULL
reveals	NULL
the	NULL
amount	NULL
of	NULL
UDG	NULL
expressed	NULL
in	NULL
these	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Immunochemical	NULL
rosetting	NULL
of	NULL
CD19*	NULL
cells	NULL
cotransfected	NULL
with	NULL
pCMV/UDGa	NULL
reveal	NULL
,	NULL
by	NULL
flow	NULL
cytometry	NULL
,	NULL
a	NULL
substantially	NULL
high	NULL
proportion	NULL
of	NULL
pCMV/UDGa-transfected	NULL
cells	NULL
were	NULL
retained	NULL
in	NULL
G/G	NULL
,	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
in	NULL
the	NULL
following	NULL
48	NULL
h	NULL
after	NULL
transfection	NULL
as	NULL
shown	NULL
in	NULL
Table	NULL
I	NULL
.	NULL

Comparatively	NULL
,	NULL
the	NULL
negative	NULL
control	NULL
cotransfected	NULL
with	NULL
pCMV/O	NULL
expressed	NULL
a	NULL
relatively	NULL
even	NULL
distribution	NULL
of	NULL
cells	NULL
in	NULL
GG	NULL
,	NULL
,	NULL
S	NULL
,	NULL
and	NULL
G/M	NULL
and	NULL
asynchronous	NULL
growth	NULL
kinetics	NULL
remained	NULL
throughout	NULL
The	NULL
UDG	NULL
Gene	NULL
Product	NULL
Inhibits	NULL
E2F-1-mediated	NULL
Transcription	NULL
Saos	NULL
2	NULL
w	NULL
QC	NULL
»	NULL
®	NULL
;	NULL
P	NULL
Co	NULL
{	NULL
®	NULL
$	NULL
¢	NULL
76k-	NULL
54k-	NULL
37k-	NULL
27k-	NULL
18k-	NULL
Fic	NULL
.	NULL

4	NULL
.	NULL

Abundant	NULL
overexpression	NULL
of	NULL
the	NULL
uracil-DNA	NULL
glycosylase	NULL
gene	NULL
product	NULL
.	NULL

Immunoblot	NULL
analysis	NULL
of	NULL
cellular	NULL
extracts	NULL
prepared	NULL
from	NULL
enriched	NULL
CD19*	NULL
Saos	NULL
2	NULL
cells	NULL
48	NULL
h	NULL
following	NULL
the	NULL
cotransfection	NULL
with	NULL
a	NULL
CD19	NULL
expression	NULL
vector	NULL
along	NULL
with	NULL
either	NULL
pCMV/O	NULL
or	NULL
pCMV/UDGa	NULL
,	NULL
respectively	NULL
.	NULL

Approximately	NULL
4	NULL
x	NULL
10°	NULL
Saos	NULL
2	NULL
cells	NULL
,	NULL
selected	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
CD19*	NULL
cells	NULL
after	NULL
cotransfections	NULL
,	NULL
were	NULL
analyzed	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
recombinant	NULL
UDG	NULL
.	NULL

Each	NULL
of	NULL
three	NULL
individual	NULL
cotransfections	NULL
were	NULL
were	NULL
pooled	NULL
together	NULL
,	NULL
then	NULL
lysed	NULL
,	NULL
and	NULL
cleared	NULL
of	NULL
cellular	NULL
debris	NULL
.	NULL

Twenty-five	NULL
ug	NULL
of	NULL
cellular	NULL
protein	NULL
in	NULL
each	NULL
lane	NULL
were	NULL
separated	NULL
by	NULL
SDS-PAGE	NULL
and	NULL
transferred	NULL
to	NULL
polyvinylidene	NULL
difluoride	NULL
membranes	NULL
.	NULL

Immunoblots	NULL
were	NULL
performed	NULL
using	NULL
a	NULL
primary	NULL
monoclonal	NULL
antibody	NULL
,	NULL
mAb-u	NULL
(	NULL
91-243	NULL
)	NULL
,	NULL
directed	NULL
against	NULL
an	NULL
internal	NULL
cyclin-like	NULL
domain	NULL
(	NULL
Thr®	NULL
'	NULL
to	NULL
e	NULL
``	NULL
``	NULL
)	NULL
of	NULL
UDG	NULL
.	NULL

Prestained	NULL
molecular	NULL
weight	NULL
protein	NULL
markers	NULL
were	NULL
used	NULL
to	NULL
predict	NULL
the	NULL
size	NULL
of	NULL
the	NULL
proteins	NULL
detected	NULL
.	NULL

the	NULL
times	NULL
examined	NULL
.	NULL

Examination	NULL
of	NULL
these	NULL
cells	NULL
,	NULL
by	NULL
measuring	NULL
DNA	NULL
synthesis	NULL
(	NULL
BrdUrd	NULL
incorporation	NULL
)	NULL
and	NULL
DNA	NULL
content	NULL
,	NULL
indicate	NULL
the	NULL
relatively	NULL
disproportionate	NULL
number	NULL
of	NULL
cells	NULL
retained	NULL
in	NULL
G	NULL
,	NULL
are	NULL
from	NULL
cells	NULL
between	NULL
48-72	NULL
h	NULL
after	NULL
transfection	NULL
with	NULL
pCMV/UDGa	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

This	NULL
is	NULL
in	NULL
contrast	NULL
to	NULL
Saos	NULL
2	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
control	NULL
vector	NULL
pCMV/O	NULL
which	NULL
provide	NULL
relatively	NULL
even	NULL
distribution	NULL
of	NULL
cells	NULL
in	NULL
late	NULL
S	NULL
phase	NULL
with	NULL
a	NULL
substantial	NULL
population	NULL
of	NULL
cells	NULL
entering	NULL
G	NULL
;	NULL
,	NULL
/M	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

The	NULL
distribution	NULL
of	NULL
CD19*	NULL
cells	NULL
transiently	NULL
overexpressing	NULL
UDG	NULL
after	NULL
72	NULL
h	NULL
indicates	NULL
a	NULL
very	NULL
slight	NULL
increase	NULL
in	NULL
the	NULL
percentage	NULL
of	NULL
CD19-positive	NULL
cells	NULL
entering	NULL
S	NULL
,	NULL
when	NULL
compared	NULL
at	NULL
48	NULL
h.	NULL
But	NULL
it	NULL
is	NULL
not	NULL
until	NULL
after	NULL
96	NULL
h	NULL
that	NULL
a	NULL
major	NULL
increase	NULL
in	NULL
the	NULL
percentage	NULL
of	NULL
the	NULL
CD19	NULL
*	NULL
cell	NULL
population	NULL
are	NULL
synchronized	NULL
in	NULL
S.	NULL
This	NULL
delay	NULL
in	NULL
the	NULL
entry	NULL
into	NULL
S	NULL
was	NULL
also	NULL
established	NULL
by	NULL
[	NULL
°H	NULL
}	NULL
thymidine	NULL
incorporation	NULL
studies	NULL
.	NULL

These	NULL
studies	NULL
performed	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
indicate	NULL
that	NULL
very	NULL
few	NULL
CD19	NULL
*	NULL
Saos	NULL
2	NULL
cells	NULL
,	NULL
transiently	NULL
overexpressing	NULL
UDG	NULL
,	NULL
do	NULL
not	NULL
begin	NULL
to	NULL
move	NULL
into	NULL
the	NULL
DNA	NULL
replicative	NULL
phase	NULL
until	NULL
96	NULL
h	NULL
following	NULL
the	NULL
cotransfections	NULL
performed	NULL
.	NULL

This	NULL
is	NULL
in	NULL
contrast	NULL
to	NULL
the	NULL
amount	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
seen	NULL
in	NULL
the	NULL
control	NULL
set	NULL
.	NULL

Interestingly	NULL
,	NULL
analogous	NULL
results	NULL
have	NULL
been	NULL
obtained	NULL
through	NULL
the	NULL
microinjection	NULL
of	NULL
a	NULL
functional	NULL
Rb	NULL
gene	NULL
product	NULL
in	NULL
Saos	NULL
2	NULL
cells	NULL
,	NULL
lacking	NULL
the	NULL
normal	NULL
Rb	NULL
phenotype	NULL
(	NULL
44	NULL
)	NULL
,	NULL
and	NULL
by	NULL
transient	NULL
cotransfection	NULL
studies	NULL
(	NULL
45	NULL
,	NULL
46	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
indicate	NULL
that	NULL
abundant	NULL
overexpression	NULL
of	NULL
UDG	NULL
results	NULL
in	NULL
either	NULL
the	NULL
gross	NULL
extension	NULL
of	NULL
G	NULL
,	NULL
or	NULL
a	NULL
delay	NULL
into	NULL
the	NULL
entry	NULL
of	NULL
the	NULL
S	NULL
phase	NULL
,	NULL
but	NULL
not	NULL
the	NULL
complete	NULL
arrest	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
in	NULL
G	NULL
,	NULL
.	NULL

The	NULL
5295	NULL
results	NULL
shown	NULL
evaluated	NULL
by	NULL
flow	NULL
cytometric	NULL
staining	NULL
at	NULL
36	NULL
,	NULL
48	NULL
,	NULL
72	NULL
,	NULL
and	NULL
96	NULL
h	NULL
in	NULL
triplicate	NULL
transfections	NULL
indicate	NULL
the	NULL
progression	NULL
of	NULL
the	NULL
S	NULL
phase	NULL
continued	NULL
between	NULL
72	NULL
and	NULL
96	NULL
h	NULL
after	NULL
cotransfections	NULL
were	NULL
performed	NULL
.	NULL

Therefore	NULL
,	NULL
these	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
delayed	NULL
progression	NULL
of	NULL
S	NULL
phase	NULL
is	NULL
temporary	NULL
and	NULL
is	NULL
a	NULL
result	NULL
of	NULL
the	NULL
abundant	NULL
exogenous	NULL
expression	NULL
of	NULL
UDG	NULL
in	NULL
Saos	NULL
2	NULL
cells	NULL
.	NULL

Uracil-DNA	NULL
Glycosylase	NULL
Down-regulates	NULL
Transcription	NULL
of	NULL
the	NULL
Human	NULL
UDG	NULL
Gene	NULL
Promoter	NULL
Through	NULL
an	NULL
E2F	NULL
Consensus	NULL
Ele-ment-Because	NULL
of	NULL
the	NULL
relationship	NULL
of	NULL
abundant	NULL
UDG	NULL
expression	NULL
to	NULL
the	NULL
disruption	NULL
of	NULL
normal	NULL
cell	NULL
cycle	NULL
processes	NULL
and	NULL
relative	NULL
cyclin-like	NULL
homology	NULL
,	NULL
we	NULL
were	NULL
interested	NULL
in	NULL
understanding	NULL
the	NULL
potential	NULL
of	NULL
this	NULL
nuclear	NULL
species	NULL
of	NULL
UDG	NULL
(	NULL
1	NULL
)	NULL
to	NULL
participate	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
its	NULL
own	NULL
promoter	NULL
through	NULL
an	NULL
E2F	NULL
target	NULL
.	NULL

This	NULL
could	NULL
be	NULL
tested	NULL
through	NULL
the	NULL
use	NULL
of	NULL
UDG	NULL
gene	NULL
promoter/reporter	NULL
constructs	NULL
UDG	NULL
constructs	NULL
D/wt	NULL
and	NULL
UDG	NULL
construct	NULL
D/mut	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Constitutive	NULL
and	NULL
high	NULL
level	NULL
expression	NULL
of	NULL
this	NULL
species	NULL
of	NULL
UDG	NULL
was	NULL
performed	NULL
by	NULL
the	NULL
cotransfection	NULL
of	NULL
pCMV/	NULL
UDGa	NULL
in	NULL
a	NULL
transient	NULL
expression	NULL
assay	NULL
with	NULL
UDG	NULL
construct-D/wt	NULL
and	NULL
UDG	NULL
construct-D/mut	NULL
serving	NULL
as	NULL
targets	NULL
for	NULL
the	NULL
ef-fectors	NULL
E2F-1	NULL
and	NULL
UDG	NULL
,	NULL
individually	NULL
.	NULL

An	NULL
_	NULL
experiment	NULL
performed	NULL
,	NULL
with	NULL
results	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
demonstrates	NULL
the	NULL
potential	NULL
of	NULL
E2F-1	NULL
to	NULL
transactivate	NULL
as	NULL
well	NULL
as	NULL
the	NULL
ability	NULL
of	NULL
UDG	NULL
to	NULL
repress	NULL
expression	NULL
of	NULL
CAT	NULL
through	NULL
the	NULL
identical	NULL
promoter	NULL
constructs	NULL
shown	NULL
in	NULL
the	NULL
figure	NULL
.	NULL

Fig	NULL
.	NULL

5	NULL
provides	NULL
comparative	NULL
quantitation	NULL
of	NULL
CAT	NULL
activity	NULL
expressed	NULL
by	NULL
both	NULL
E2F-1	NULL
and	NULL
UDG	NULL
separately	NULL
in	NULL
a	NULL
transfection	NULL
assay	NULL
.	NULL

Transient	NULL
expression	NULL
of	NULL
human	NULL
UDG	NULL
,	NULL
directed	NULL
by	NULL
the	NULL
cytomegalovirus	NULL
immediate-early	NULL
promoter	NULL
,	NULL
down-regulates	NULL
expression	NULL
of	NULL
the	NULL
CAT	NULL
using	NULL
UDG	NULL
construct	NULL
D/wt	NULL
.	NULL

The	NULL
activity	NULL
indicates	NULL
between	NULL
a	NULL
3-4-fold	NULL
decline	NULL
in	NULL
Saos	NULL
2	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
when	NULL
compared	NULL
to	NULL
the	NULL
cotransfection	NULL
experiments	NULL
performed	NULL
with	NULL
the	NULL
vector	NULL
control	NULL
pCMV/O	NULL
.	NULL

Interestingly	NULL
,	NULL
site-directed	NULL
mutations	NULL
within	NULL
the	NULL
only	NULL
E2F-1	NULL
site	NULL
left	NULL
,	NULL
represented	NULL
as	NULL
UDG	NULL
construct	NULL
D/mut	NULL
,	NULL
show	NULL
that	NULL
the	NULL
majority	NULL
of	NULL
CAT	NULL
activity	NULL
is	NULL
presumably	NULL
due	NULL
largely	NULL
to	NULL
endoge-nous	NULL
cellular	NULL
E2F	NULL
activation	NULL
.	NULL

We	NULL
show	NULL
that	NULL
repression	NULL
of	NULL
E2F-mediated	NULL
transcription	NULL
is	NULL
due	NULL
to	NULL
the	NULL
high	NULL
levels	NULL
of	NULL
UDG	NULL
gene	NULL
product	NULL
expression	NULL
in	NULL
the	NULL
transient	NULL
transfection	NULL
assay	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
the	NULL
action	NULL
by	NULL
which	NULL
UDG	NULL
targets	NULL
repression	NULL
of	NULL
transcription	NULL
is	NULL
through	NULL
an	NULL
E2F	NULL
target	NULL
.	NULL

Although	NULL
these	NULL
mutations	NULL
reduce	NULL
much	NULL
of	NULL
the	NULL
expression	NULL
exhibited	NULL
by	NULL
the	NULL
UDG	NULL
promoter	NULL
,	NULL
extending	NULL
445	NULL
nucleotides	NULL
upstream	NULL
of	NULL
the	NULL
reported	NULL
transcriptional	NULL
start	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
,	NULL
the	NULL
E2F	NULL
site	NULL
is	NULL
the	NULL
target	NULL
for	NULL
the	NULL
autoregulation	NULL
of	NULL
UDG	NULL
gene	NULL
transcription	NULL
.	NULL

UDG	NULL
Down-regulates	NULL
the	NULL
Adenovirus	NULL
E2	NULL
Promoter-Due	NULL
to	NULL
some	NULL
sequence	NULL
similarity	NULL
and	NULL
positioning	NULL
of	NULL
two	NULL
E2F	NULL
sites	NULL
found	NULL
between	NULL
the	NULL
human	NULL
UDG	NULL
promoter	NULL
and	NULL
the	NULL
adenoviral	NULL
E2	NULL
gene	NULL
promoter	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
transiently	NULL
expressed	NULL
UDG	NULL
enzyme	NULL
with	NULL
the	NULL
heterologous	NULL
viral	NULL
E2	NULL
gene	NULL
promoter	NULL
.	NULL

Indication	NULL
that	NULL
the	NULL
down-regulation	NULL
of	NULL
E2F-mediated	NULL
transcription	NULL
is	NULL
expressed	NULL
by	NULL
UDG	NULL
in	NULL
transient	NULL
transfection	NULL
assay	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

This	NULL
prompted	NULL
us	NULL
to	NULL
distinguish	NULL
this	NULL
activity	NULL
in	NULL
a	NULL
heterologous	NULL
E2F-responsive	NULL
gene	NULL
.	NULL

Using	NULL
the	NULL
adenovirus	NULL
E2	NULL
promoter	NULL
as	NULL
a	NULL
target	NULL
promoter	NULL
,	NULL
we	NULL
tested	NULL
our	NULL
hypothesis	NULL
that	NULL
UDG	NULL
targets	NULL
the	NULL
inhibition	NULL
of	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
.	NULL

Cotransfections	NULL
were	NULL
performed	NULL
using	NULL
both	NULL
pE2-CAT	NULL
and	NULL
pCMV/UDGa	NULL
demonstrate	NULL
the	NULL
ability	NULL
of	NULL
UDG	NULL
to	NULL
down-regulate	NULL
CAT	NULL
expression	NULL
directed	NULL
by	NULL
the	NULL
E2	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

Quantitation	NULL
of	NULL
these	NULL
results	NULL
consistently	NULL
indicated	NULL
more	NULL
than	NULL
a	NULL
2-fold	NULL
reduction	NULL
in	NULL
the	NULL
amount	NULL
of	NULL
CAT	NULL
expressed	NULL
when	NULL
compared	NULL
to	NULL
cotransfections	NULL
performed	NULL
with	NULL
the	NULL
vector	NULL
control	NULL
,	NULL
pCMV/O	NULL
.	NULL

DISCUSSION	NULL
Examples	NULL
of	NULL
DNA	NULL
repair	NULL
have	NULL
recently	NULL
been	NULL
shown	NULL
to	NULL
overlap	NULL
with	NULL
mechanisms	NULL
of	NULL
transcriptional	NULL
control	NULL
(	NULL
46-50	NULL
)	NULL
.	NULL

The	NULL
gene	NULL
for	NULL
a	NULL
novel	NULL
cyclin-like	NULL
uracil-DNA	NULL
glycosylase	NULL
that	NULL
encodes	NULL
a	NULL
predicted	NULL
36-kDa	NULL
cell	NULL
cycle-regulated	NULL
DNA	NULL
repair	NULL
en-	NULL
5296	NULL
The	NULL
UDG	NULL
Gene	NULL
Product	NULL
Inhibits	NULL
E2F-1-mediated	NULL
Transcription	NULL
TaBte	NULL
I	NULL
Cell	NULL
cycle	NULL
profile	NULL
of	NULL
CD19-positive	NULL
Saos	NULL
2	NULL
cells	NULL
cotransfected	NULL
with	NULL
both	NULL
a	NULL
CD19	NULL
and	NULL
UDG	NULL
expression	NULL
plasmids	NULL
Approximately	NULL
4	NULL
X	NULL
10°	NULL
Saos	NULL
2	NULL
cells	NULL
were	NULL
selected	NULL
for	NULL
the	NULL
cell	NULL
surface	NULL
marker	NULL
CD19	NULL
with	NULL
magnetically	NULL
conjugated	NULL
anti-CD19	NULL
beads	NULL
(	NULL
Dynal	NULL
,	NULL
Inc.	NULL
)	NULL
and	NULL
uniformally	NULL
detached	NULL
from	NULL
the	NULL
beads	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

CD19*	NULL
populations	NULL
of	NULL
Saos	NULL
2	NULL
cells	NULL
from	NULL
individual	NULL
cotransfection	NULL
experiments	NULL
were	NULL
analyzed	NULL
by	NULL
FACS	NULL
(	NULL
Becton	NULL
Dickson	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

Following	NULL
the	NULL
time	NULL
points	NULL
indicated	NULL
(	NULL
hours	NULL
after	NULL
transfection	NULL
)	NULL
,	NULL
incorporation	NULL
of	NULL
(	NULL
BrdU	NULL
)	NULL
into	NULL
CD19*	NULL
cells	NULL
was	NULL
conducted	NULL
over	NULL
a	NULL
60-min	NULL
incubation	NULL
then	NULL
isolated	NULL
nuclei	NULL
were	NULL
labeled	NULL
with	NULL
propidium	NULL
iodide	NULL
.	NULL

Bivariant	NULL
FACScan	NULL
analysis	NULL
of	NULL
both	NULL
BrdU	NULL
incorporation	NULL
(	NULL
DNA	NULL
synthesis	NULL
)	NULL
and	NULL
DNA	NULL
content	NULL
established	NULL
the	NULL
percentage	NULL
of	NULL
CD19	NULL
positive	NULL
cells	NULL
detected	NULL
at	NULL
defined	NULL
stages	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
table	NULL
.	NULL

Values	NULL
represent	NULL
the	NULL
mean	NULL
+	NULL
the	NULL
standard	NULL
deviation	NULL
from	NULL
three	NULL
separate	NULL
cotransfection	NULL
experiments	NULL
.	NULL

Hours	NULL
post-	NULL
Transfecti	NULL
°H	NULL
)	NULL
Thymidi	NULL
transfegtion	NULL
raﬁcﬁfrmn	NULL
C	NULL
)	NULL
/G	NULL
8	NULL
G/M	NULL
[	NULL
incgrpglfgéios	NULL
‘	NULL
f	NULL
36	NULL
pCMV/O	NULL
53.2	NULL
+	NULL
3.6	NULL
31.3	NULL
*	NULL
4.5	NULL
15.5	NULL
+	NULL
5.2	NULL
5,217	NULL
+	NULL
948	NULL
pCMV/UDGa	NULL
58.2	NULL
+	NULL
2.1	NULL
18.9	NULL
+	NULL
3.2	NULL
22.9	NULL
1	NULL
5.6	NULL
3,349	NULL
+	NULL
488	NULL
48	NULL
pCMV/O	NULL
46.2	NULL
+	NULL
2.7	NULL
34.3	NULL
+	NULL
5.1	NULL
19.5	NULL
*	NULL
2.7	NULL
4,437	NULL
£	NULL
1,250	NULL
pCMV/UDGa	NULL
83.4	NULL
+	NULL
6.2	NULL
5.7	NULL
+	NULL
0.4	NULL
10.9	NULL
x	NULL
1.7	NULL
1,151	NULL
*	NULL
278	NULL
72	NULL
pCMV/O	NULL
49.8	NULL
*	NULL
6.4	NULL
29.4	NULL
+	NULL
4.9	NULL
20.8	NULL
+	NULL
8.2	NULL
5,455	NULL
+	NULL
1,820	NULL
pCMV/UDGa	NULL
72.7	NULL
*	NULL
8.3	NULL
11.2	NULL
*	NULL
3.7	NULL
16.1	NULL
*	NULL
4.7	NULL
824	NULL
*	NULL
154	NULL
96	NULL
pCMV/O	NULL
51.4	NULL
*	NULL
7.1	NULL
85.8	NULL
+	NULL
4.2	NULL
12.8	NULL
+	NULL
3.8	NULL
6,755	NULL
+	NULL
1,672	NULL
pCMV/UDGa	NULL
29.8	NULL
+	NULL
4.9	NULL
66.3	NULL
+	NULL
6.8	NULL
3.9	NULL
+	NULL
0.7	NULL
12,851	NULL
+	NULL
8,129	NULL
*	NULL
Incorporation	NULL
of	NULL
[	NULL
*HIthymidine	NULL
.	NULL

CD19*	NULL
cells	NULL
cotransfected	NULL
with	NULL
either	NULL
pCMV/UDGa	NULL
or	NULL
pCMV/0	NULL
were	NULL
monitored	NULL
for	NULL
the	NULL
incorporation	NULL
of	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
following	NULL
36	NULL
,	NULL
48	NULL
,	NULL
72	NULL
,	NULL
and	NULL
96	NULL
h	NULL
after	NULL
transfection	NULL
.	NULL

Values	NULL
represent	NULL
the	NULL
mean	NULL
incorporation	NULL
[	NULL
counts/min	NULL
(	NULL
cpm	NULL
)	NULL
]	NULL
+	NULL
the	NULL
standard	NULL
deviation	NULL
from	NULL
three	NULL
separate	NULL
labeling	NULL
experiments	NULL
using	NULL
[	NULL
°H	NULL
)	NULL
thymidine	NULL
.	NULL

&	NULL
«	NULL
8	NULL
A.	NULL
Spt	NULL
E2F	NULL
C	NULL
--	NULL
--	NULL
-~	NULL
--	NULL
-	NULL
4-3	NULL
»	NULL
445	NULL
+81	NULL
\	NULL
UDG	NULL
Construct	NULL
»	NULL
Diwt	NULL
pCMvid	NULL
m	NULL
L	NULL
``	NULL
I	NULL
Sp1	NULL
_	NULL
E2F/imut	NULL
pCMV/E2F-1	NULL
--	NULL
-I	NULL
,	NULL
~	NULL
Kj	NULL
}	NULL
.	NULL

‘	NULL
A5	NULL
+81	NULL
_	NULL
pemvio	NULL
UDG	NULL
Construct-	NULL
D/mut	NULL
B.	NULL
Sp1	NULL
__	NULL
gare	NULL
PCMVUDG	NULL
«	NULL
C	NULL
--	NULL
--	NULL
--	NULL
~	NULL
-m	NULL
+4	NULL
T	NULL
'	NULL
#	NULL
sam	NULL
RWSS	NULL
C	NULL
DG	NULL
Construct-	NULL
D/iwt	NULL
--	NULL
-	NULL
excet	NULL
-*	NULL
Spi	NULL
_	NULL
§	NULL
--	NULL
Negatve	NULL
*	NULL
+8	NULL
``	NULL
-	NULL
pewivo	NULL
k\\	NULL
-A	NULL
**	NULL
``	NULL
_	NULL
Control	NULL
UDG	NULL
Construct	NULL
Oimut	NULL
4	NULL
)	NULL
-+-102	NULL
3	NULL
4	NULL
5	NULL
20	NULL
25	NULL
30	NULL
35	NULL
40	NULL
4§	NULL
50	NULL
55	NULL
CAT	NULL
Activity	NULL
(	NULL
%	NULL
Acetylation	NULL
)	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

UDG	NULL
expression	NULL
down-regulates	NULL
human	NULL
UDG	NULL
gene	NULL
promoter	NULL
activity	NULL
at	NULL
an	NULL
E2F	NULL
site	NULL
.	NULL

A	NULL
,	NULL
examination	NULL
of	NULL
CAT	NULL
activity	NULL
mediated	NULL
by	NULL
a	NULL
transiently	NULL
expressed	NULL
E2F-1	NULL
cDNA	NULL
on	NULL
a	NULL
wild	NULL
type	NULL
and	NULL
mutant	NULL
E2F	NULL
consensus	NULL
element	NULL
,	NULL
using	NULL
the	NULL
UDG	NULL
gene	NULL
promoter	NULL
target	NULL
to	NULL
direct	NULL
expression	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
.	NULL

Human	NULL
UDG	NULL
promoter	NULL
constructs	NULL
,	NULL
UDG	NULL
constructs-D/wt	NULL
,	NULL
and	NULL
UDG	NULL
construct-D/mut	NULL
were	NULL
previously	NULL
shown	NULL
(	NULL
see	NULL
also	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

The	NULL
effector	NULL
plasmid	NULL
expression	NULL
vector	NULL
pCMV/E2F-1	NULL
contains	NULL
the	NULL
E2F-1	NULL
cDNA	NULL
.	NULL

The	NULL
parental	NULL
minus	NULL
expression	NULL
vector	NULL
,	NULL
pCMV/0	NULL
,	NULL
was	NULL
used	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
in	NULL
each	NULL
experimental	NULL
set	NULL
.	NULL

Cotransfections	NULL
were	NULL
performed	NULL
with	NULL
effector	NULL
expression	NULL
vector	NULL
and	NULL
target	NULL
minigene	NULL
reporter	NULL
(	NULL
as	NULL
shown	NULL
)	NULL
.	NULL

Included	NULL
in	NULL
each	NULL
cotransfection	NULL
performed	NULL
was	NULL
an	NULL
internal	NULL
control	NULL
to	NULL
standardize	NULL
the	NULL
transfection	NULL
efficiency	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
evaluated	NULL
as	NULL
percent	NULL
acetylated	NULL
radiolabeled	NULL
chloramphenicol	NULL
as	NULL
indicated	NULL
by	NULL
the	NULL
histogram	NULL
.	NULL

Solid	NULL
box	NULL
represents	NULL
the	NULL
wild	NULL
type	NULL
E2F	NULL
sequence	NULL
.	NULL

Open	NULL
box	NULL
with	NULL
an	NULL
X	NULL
represents	NULL
a	NULL
mutated	NULL
E2F	NULL
consensus	NULL
element	NULL
.	NULL

Open	NULL
box	NULL
indicates	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
Sp1	NULL
consensus	NULL
located	NULL
directly	NULL
upstream	NULL
of	NULL
the	NULL
E2F	NULL
target	NULL
.	NULL

Standard	NULL
errors	NULL
were	NULL
calculated	NULL
from	NULL
the	NULL
results	NULL
of	NULL
five	NULL
individual	NULL
transfection	NULL
experiments	NULL
performed	NULL
with	NULL
two	NULL
separate	NULL
plasmid	NULL
DNA	NULL
preparations	NULL
.	NULL

Standard	NULL
error	NULL
is	NULL
indicated	NULL
by	NULL
the	NULL
error	NULL
bars	NULL
.	NULL

B	NULL
,	NULL
examination	NULL
of	NULL
CAT	NULL
activity	NULL
mediated	NULL
by	NULL
a	NULL
transiently	NULL
expressed	NULL
UDG	NULL
cDNA	NULL
on	NULL
a	NULL
wild	NULL
type	NULL
and	NULL
mutant	NULL
E2F	NULL
consensus	NULL
element	NULL
,	NULL
using	NULL
the	NULL
UDG	NULL
gene	NULL
promoter	NULL
target	NULL
to	NULL
direct	NULL
expression	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
.	NULL

CAT	NULL
activities	NULL
were	NULL
comparatively	NULL
measured	NULL
to	NULL
indicate	NULL
the	NULL
relative	NULL
amount	NULL
of	NULL
acetylation	NULL
between	NULL
each	NULL
experimental	NULL
set	NULL
.	NULL

zyme	NULL
has	NULL
been	NULL
previously	NULL
reported	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Here	NULL
we	NULL
have	NULL
demon-	NULL
-	NULL
calized	NULL
the	NULL
sequences	NULL
responsive	NULL
to	NULL
EZF-1	NULL
within	NULL
the	NULL
UDG	NULL
strated	NULL
the	NULL
relationship	NULL
of	NULL
the	NULL
E2F-1	NULL
transcription	NULL
factor	NULL
to	NULL
-	NULL
promoter	NULL
.	NULL

The	NULL
regulation	NULL
of	NULL
UDG	NULL
by	NULL
the	NULL
cell	NULL
cycle-dependent	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
UDG	NULL
promoter	NULL
.	NULL

We	NULL
have	NULL
lo-	NULL
-	NULL
activity	NULL
of	NULL
E2F-1	NULL
provides	NULL
evidence	NULL
for	NULL
converging	NULL
mechanisms	NULL
The	NULL
UDG	NULL
Gene	NULL
Product	NULL
Inhibits	NULL
E2F-1-mediated	NULL
Transcription	NULL
A	NULL
.	NULL

CAT	NULL
pE2-CAT	NULL
Th—	NULL
E2F	NULL
double	NULL
site	NULL
B	NULL
.	NULL

Expression	NULL
vector	NULL
rove	NULL
y-C	NULL
f	NULL
-t	NULL
--	NULL
--	NULL
--	NULL
--	NULL
$	NULL
10	NULL
sq	NULL
40	NULL
60	NULL
80	NULL
100	NULL
CAT	NULL
Activity	NULL
(	NULL
%	NULL
Acetylation	NULL
)	NULL
Fic	NULL
.	NULL

6	NULL
.	NULL

Expression	NULL
of	NULL
UDG	NULL
can	NULL
down-regulate	NULL
a	NULL
heterologous	NULL
promoter	NULL
in	NULL
Saos	NULL
2	NULL
cells	NULL
.	NULL

A	NULL
,	NULL
schematic	NULL
of	NULL
the	NULL
reporter	NULL
minigene	NULL
construct	NULL
used	NULL
in	NULL
the	NULL
cotransfection	NULL
experiment	NULL
.	NULL

The	NULL
adenovirus	NULL
E2	NULL
promoter	NULL
was	NULL
used	NULL
as	NULL
a	NULL
target	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
UDG	NULL
,	NULL
contains	NULL
E2	NULL
promoter	NULL
sequences	NULL
extending	NULL
from	NULL
-408	NULL
to	NULL
+	NULL
7	NULL
relative	NULL
to	NULL
the	NULL
site	NULL
of	NULL
transcription	NULL
fused	NULL
to	NULL
the	NULL
bacterial	NULL
CAT	NULL
gene	NULL
.	NULL

Nucleotide	NULL
sequence	NULL
indicates	NULL
the	NULL
E2F	NULL
protein	NULL
binding	NULL
consensus	NULL
located	NULL
within	NULL
the	NULL
adenoviral	NULL
E2	NULL
gene	NULL
promoter	NULL
.	NULL

B	NULL
,	NULL
cotransfections	NULL
were	NULL
performed	NULL
using	NULL
the	NULL
adenovirus	NULL
E2	NULL
promoter	NULL
target	NULL
along	NULL
with	NULL
either	NULL
the	NULL
UDG	NULL
expression	NULL
plasmid	NULL
,	NULL
pCMV/UDGa	NULL
«	NULL
,	NULL
or	NULL
the	NULL
control	NULL
plasmid	NULL
,	NULL
pCMV/0	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
measured	NULL
by	NULL
the	NULL
phase-extraction	NULL
method	NULL
and	NULL
quantitated	NULL
.	NULL

Relative	NULL
CAT	NULL
activity	NULL
is	NULL
presented	NULL
as	NULL
percent	NULL
acetylation	NULL
.	NULL

The	NULL
standard	NULL
error	NULL
was	NULL
calculated	NULL
from	NULL
eight	NULL
separate	NULL
transfections	NULL
using	NULL
two	NULL
separate	NULL
plasmid	NULL
DNA	NULL
preparations	NULL
.	NULL

The	NULL
standard	NULL
error	NULL
is	NULL
represented	NULL
by	NULL
the	NULL
error	NULL
bars	NULL
shown	NULL
in	NULL
the	NULL
histogram	NULL
.	NULL

between	NULL
transcription	NULL
,	NULL
DNA	NULL
repair	NULL
and	NULL
cell	NULL
cycle	NULL
events	NULL
leading	NULL
to	NULL
DNA	NULL
replication	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
have	NULL
tested	NULL
the	NULL
potential	NULL
for	NULL
the	NULL
cyclin-like	NULL
species	NULL
of	NULL
UDG	NULL
itself	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
transcriptional	NULL
control	NULL
through	NULL
an	NULL
E2F-mediated	NULL
regulatory	NULL
element	NULL
.	NULL

Recent	NULL
evidence	NULL
to	NULL
support	NULL
the	NULL
role	NULL
(	NULL
s	NULL
)	NULL
of	NULL
E2F-1	NULL
as	NULL
an	NULL
important	NULL
regulator	NULL
of	NULL
many	NULL
cell	NULL
cycle	NULL
events	NULL
,	NULL
including	NULL
apotosis	NULL
,	NULL
may	NULL
be	NULL
an	NULL
example	NULL
of	NULL
the	NULL
ability	NULL
of	NULL
E2F-1	NULL
to	NULL
overcome	NULL
cell	NULL
cycle	NULL
checkpoints	NULL
mediated	NULL
by	NULL
both	NULL
Rb	NULL
and	NULL
p53	NULL
(	NULL
51	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
these	NULL
results	NULL
implicate	NULL
one	NULL
species	NULL
of	NULL
UDG	NULL
in	NULL
the	NULL
alteration	NULL
of	NULL
E2F	NULL
-mediated	NULL
transcription	NULL
.	NULL

This	NULL
raises	NULL
the	NULL
possibility	NULL
that	NULL
pathways	NULL
that	NULL
integrate	NULL
transcriptional	NULL
control	NULL
with	NULL
cell	NULL
cycle	NULL
events	NULL
,	NULL
through	NULL
E2F	NULL
,	NULL
may	NULL
also	NULL
integrate	NULL
cellular	NULL
factors	NULL
involved	NULL
in	NULL
the	NULL
response	NULL
to	NULL
and	NULL
repair	NULL
of	NULL
damaged	NULL
DNA	NULL
.	NULL

Indication	NULL
of	NULL
the	NULL
involvement	NULL
of	NULL
E2F-1	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
UDG	NULL
gene	NULL
transcription	NULL
documents	NULL
a	NULL
mechanism	NULL
likely	NULL
involved	NULL
in	NULL
the	NULL
cell	NULL
cycle-dependent	NULL
expression	NULL
of	NULL
human	NULL
cyclin-like	NULL
UDG	NULL
.	NULL

Although	NULL
this	NULL
does	NULL
not	NULL
preclude	NULL
the	NULL
role	NULL
of	NULL
other	NULL
transcription	NULL
factors	NULL
in	NULL
the	NULL
cell	NULL
cycle	NULL
regulation	NULL
of	NULL
the	NULL
UDG	NULL
gene	NULL
,	NULL
including	NULL
Sp1	NULL
,	NULL
we	NULL
suggest	NULL
that	NULL
E2F	NULL
may	NULL
require	NULL
interactions	NULL
with	NULL
other	NULL
factors	NULL
that	NULL
equally	NULL
contribute	NULL
to	NULL
the	NULL
cell	NULL
cycle-dependent	NULL
regulation	NULL
of	NULL
UDG	NULL
.	NULL

In	NULL
surprising	NULL
contrast	NULL
to	NULL
our	NULL
expectations	NULL
,	NULL
recent	NULL
experiments	NULL
conducted	NULL
in	NULL
this	NULL
laboratory	NULL
suggest	NULL
that	NULL
transient	NULL
expression	NULL
of	NULL
Rb	NULL
significantly	NULL
contributes	NULL
to	NULL
the	NULL
overall	NULL
stimulation	NULL
of	NULL
UDG	NULL
gene	NULL
transcription	NULL
through	NULL
a	NULL
combined	NULL
Rb/Sp1-responsive	NULL
element	NULL
located	NULL
upstream	NULL
of	NULL
the	NULL
UDG	NULL
promoter	NULL
.	NULL

?	NULL

Recently	NULL
,	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
both	NULL
Rb	NULL
and	NULL
Sp1	NULL
can	NULL
converge	NULL
on	NULL
a	NULL
specific	NULL
5-CCACCC-3	NULL
'	NULL
nucleotide	NULL
motif	NULL
in	NULL
the	NULL
IGF-II	NULL
gene	NULL
promoter	NULL
and	NULL
results	NULL
in	NULL
the	NULL
stimulation	NULL
of	NULL
IGF-II	NULL
gene	NULL
transcription	NULL
(	NULL
53	NULL
)	NULL
.	NULL

Despite	NULL
the	NULL
role	NULL
Rb	NULL
has	NULL
in	NULL
exerting	NULL
an	NULL
inhibitory	NULL
effect	NULL
on	NULL
E2F-1-mediated	NULL
transcription	NULL
by	NULL
interacting	NULL
with	NULL
E2F	NULL
°	NULL
K.	NULL
Spidoni	NULL
,	NULL
G.	NULL
Shue	NULL
,	NULL
and	NULL
M.	NULL
J.	NULL
Walsh	NULL
,	NULL
manuscript	NULL
submitted	NULL
for	NULL
publication	NULL
.	NULL

5297	NULL
directly	NULL
(	NULL
10	NULL
)	NULL
,	NULL
the	NULL
complexity	NULL
of	NULL
the	NULL
UDG	NULL
promoter	NULL
may	NULL
warrant	NULL
contrasting	NULL
and	NULL
competing	NULL
signals	NULL
for	NULL
Rb	NULL
interaction	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
mechanism	NULL
for	NULL
the	NULL
positive	NULL
regulation	NULL
of	NULL
UDG	NULL
may	NULL
separately	NULL
include	NULL
both	NULL
Rb	NULL
and	NULL
EZ2F-1	NULL
.	NULL

This	NULL
model	NULL
could	NULL
hypothetically	NULL
account	NULL
for	NULL
the	NULL
rapid	NULL
requirements	NULL
for	NULL
transient	NULL
UDG	NULL
expression	NULL
through	NULL
signals	NULL
associated	NULL
with	NULL
detection	NULL
of	NULL
damaged	NULL
DNA	NULL
to	NULL
initiating	NULL
a	NULL
delay	NULL
in	NULL
the	NULL
progression	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
by	NULL
simultaneously	NULL
incorporating	NULL
the	NULL
activities	NULL
of	NULL
Rb	NULL
,	NULL
Sp1	NULL
,	NULL
and	NULL
E2F-1	NULL
by	NULL
competing	NULL
for	NULL
the	NULL
affinity	NULL
of	NULL
Rb	NULL
.	NULL

We	NULL
demonstrated	NULL
that	NULL
one	NULL
physiological	NULL
result	NULL
of	NULL
the	NULL
constitutive	NULL
overexpression	NULL
of	NULL
exogenous	NULL
cyclin-like	NULL
species	NULL
of	NULL
UDG	NULL
is	NULL
the	NULL
accumulation	NULL
of	NULL
Saos2	NULL
cells	NULL
delayed	NULL
in	NULL
late	NULL
G	NULL
,	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

This	NULL
following	NULL
several	NULL
hours	NULL
after	NULL
the	NULL
transfection	NULL
of	NULL
a	NULL
UDG	NULL
expression	NULL
vector	NULL
is	NULL
shown	NULL
in	NULL
Table	NULL
L.	NULL
It	NULL
is	NULL
interesting	NULL
that	NULL
transient	NULL
overexpression	NULL
of	NULL
UDG	NULL
only	NULL
delays	NULL
the	NULL
growth	NULL
kinetics	NULL
and	NULL
then	NULL
follows	NULL
in	NULL
a	NULL
pattern	NULL
of	NULL
synchronized	NULL
entry	NULL
into	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
this	NULL
process	NULL
delays	NULL
progression	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
and	NULL
is	NULL
only	NULL
tempo-rary	NULL
,	NULL
possibly	NULL
superseded	NULL
by	NULL
more	NULL
dominant	NULL
mechanisms	NULL
for	NULL
control	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
kinetics	NULL
.	NULL

Although	NULL
the	NULL
precise	NULL
mechanism	NULL
for	NULL
this	NULL
result	NULL
has	NULL
yet	NULL
to	NULL
be	NULL
defined	NULL
,	NULL
it	NULL
is	NULL
suspected	NULL
that	NULL
the	NULL
cyclin-like	NULL
homology	NULL
of	NULL
this	NULL
UDG	NULL
species	NULL
may	NULL
be	NULL
``	NULL
in	NULL
effect	NULL
``	NULL
a	NULL
functional	NULL
component	NULL
of	NULL
UDG	NULL
,	NULL
possibly	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
a	NULL
cyclin	NULL
.	NULL

Due	NULL
to	NULL
the	NULL
vital	NULL
role	NULL
E2F	NULL
may	NULL
have	NULL
in	NULL
the	NULL
progression	NULL
of	NULL
the	NULL
replicative	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
(	NULL
51	NULL
)	NULL
,	NULL
one	NULL
strategy	NULL
to	NULL
try	NULL
to	NULL
account	NULL
for	NULL
the	NULL
potential	NULL
of	NULL
UDG	NULL
to	NULL
alter	NULL
the	NULL
progression	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
was	NULL
to	NULL
examine	NULL
the	NULL
effect	NULL
of	NULL
an	NULL
abundantly	NULL
transiently	NULL
expressed	NULL
UDG	NULL
protein	NULL
on	NULL
E2F-mediated	NULL
transcription	NULL
.	NULL

The	NULL
results	NULL
of	NULL
these	NULL
experiments	NULL
indicate	NULL
that	NULL
E2F-mediated	NULL
transcription	NULL
is	NULL
down-regulated	NULL
by	NULL
the	NULL
high	NULL
levels	NULL
and	NULL
exogenous	NULL
expression	NULL
of	NULL
UDG	NULL
(	NULL
Figs	NULL
.	NULL

5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

This	NULL
repression	NULL
occurs	NULL
through	NULL
a	NULL
mapped	NULL
E2F	NULL
target	NULL
located	NULL
proximal	NULL
to	NULL
the	NULL
transcriptional	NULL
start	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

The	NULL
apparent	NULL
regulation	NULL
of	NULL
UDG	NULL
gene	NULL
transcription	NULL
by	NULL
its	NULL
own	NULL
gene	NULL
product	NULL
may	NULL
be	NULL
analogous	NULL
to	NULL
that	NULL
seen	NULL
by	NULL
regulation	NULL
of	NULL
the	NULL
Rb	NULL
gene	NULL
by	NULL
the	NULL
Rb	NULL
gene	NULL
product	NULL
(	NULL
54	NULL
)	NULL
through	NULL
interactions	NULL
with	NULL
E2F-1	NULL
.	NULL

Despite	NULL
the	NULL
similarities	NULL
between	NULL
UDG	NULL
and	NULL
cyclin	NULL
protein	NULL
kinase	NULL
A	NULL
to	NULL
down-regulate	NULL
E2F-1-mediated	NULL
transcription	NULL
as	NULL
recently	NULL
described	NULL
(	NULL
29	NULL
)	NULL
,	NULL
there	NULL
are	NULL
significant	NULL
differences	NULL
in	NULL
the	NULL
timing	NULL
of	NULL
these	NULL
activities	NULL
during	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL
``	NULL

Therefore	NULL
,	NULL
we	NULL
do	NULL
not	NULL
know	NULL
nor	NULL
do	NULL
we	NULL
suggest	NULL
that	NULL
the	NULL
individual	NULL
activities	NULL
demonstrated	NULL
by	NULL
UDG	NULL
or	NULL
cyclin	NULL
A	NULL
on	NULL
E2ZF-l-mediated	NULL
function	NULL
occur	NULL
by	NULL
similar	NULL
biochemical	NULL
mechanisms	NULL
.	NULL

Also	NULL
,	NULL
there	NULL
is	NULL
no	NULL
evidence	NULL
in	NULL
this	NULL
report	NULL
to	NULL
suggest	NULL
the	NULL
cellular	NULL
role	NULL
of	NULL
UDG	NULL
to	NULL
be	NULL
analogous	NULL
to	NULL
the	NULL
function	NULL
of	NULL
Rb	NULL
in	NULL
vivo	NULL
.	NULL

We	NULL
believe	NULL
the	NULL
restricted	NULL
cell	NULL
growth	NULL
resulting	NULL
from	NULL
abundant	NULL
UDG	NULL
expression	NULL
may	NULL
come	NULL
as	NULL
a	NULL
result	NULL
of	NULL
biochemical	NULL
interactions	NULL
between	NULL
UDG	NULL
and	NULL
E2F-1	NULL
,	NULL
but	NULL
have	NULL
no	NULL
direct	NULL
evidence	NULL
for	NULL
this	NULL
interaction	NULL
at	NULL
the	NULL
present	NULL
time	NULL
.	NULL

It	NULL
is	NULL
also	NULL
possible	NULL
that	NULL
the	NULL
growth	NULL
inhibitory	NULL
function	NULL
of	NULL
UDG	NULL
may	NULL
also	NULL
be	NULL
a	NULL
component	NULL
of	NULL
Rb	NULL
or	NULL
related	NULL
Rb-like	NULL
nuclear	NULL
complexes	NULL
,	NULL
but	NULL
this	NULL
has	NULL
not	NULL
been	NULL
fully	NULL
evaluated	NULL
.	NULL

We	NULL
have	NULL
examined	NULL
the	NULL
activity	NULL
between	NULL
UDG	NULL
and	NULL
E2F-l-mediated	NULL
transcription	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
normal	NULL
Rb	NULL
activity	NULL
.	NULL

This	NULL
defect	NULL
in	NULL
Rb	NULL
function	NULL
is	NULL
a	NULL
characteristic	NULL
phenotype	NULL
of	NULL
osteosarcoma	NULL
Saos	NULL
2	NULL
cells	NULL
,	NULL
due	NULL
to	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
growth	NULL
inhibitory	NULL
domain	NULL
of	NULL
Rb	NULL
(	NULL
55	NULL
)	NULL
.	NULL

Despite	NULL
the	NULL
absence	NULL
of	NULL
a	NULL
normal	NULL
Rb	NULL
gene	NULL
product	NULL
observed	NULL
in	NULL
the	NULL
experiments	NULL
performed	NULL
in	NULL
this	NULL
report	NULL
,	NULL
it	NULL
may	NULL
be	NULL
interesting	NULL
to	NULL
see	NULL
if	NULL
the	NULL
p53	NULL
tumor	NULL
suppressor	NULL
gene	NULL
product	NULL
(	NULL
51	NULL
)	NULL
could	NULL
poten-tiate	NULL
the	NULL
down-regulation	NULL
of	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
mediated	NULL
by	NULL
UDG	NULL
.	NULL

We	NULL
should	NULL
note	NULL
that	NULL
expression	NULL
of	NULL
the	NULL
UDG	NULL
cDNA	NULL
in	NULL
Saos	NULL
2	NULL
cells	NULL
seems	NULL
to	NULL
produce	NULL
a	NULL
marginally	NULL
smaller	NULL
UDG	NULL
gene	NULL
product	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
from	NULL
that	NULL
previously	NULL
predicted	NULL
and	NULL
described	NULL
(	NULL
4	NULL
)	NULL
.	NULL

We	NULL
have	NULL
yet	NULL
to	NULL
account	NULL
for	NULL
this	NULL
slight	NULL
difference	NULL
from	NULL
the	NULL
predicted	NULL
*	NULL
G.	NULL
Shue	NULL
and	NULL
K.	NULL
Spidoni	NULL
,	NULL
unpublished	NULL
results	NULL
.	NULL

5298	NULL
molecular	NULL
weight	NULL
and	NULL
currently	NULL
remains	NULL
unexplained	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
overexpression	NULL
of	NULL
this	NULL
cDNA	NULL
product	NULL
in	NULL
mammalian	NULL
cells	NULL
has	NULL
not	NULL
resulted	NULL
in	NULL
any	NULL
increase	NULL
in	NULL
enzymatic	NULL
activity	NULL
associated	NULL
with	NULL
uracil-DNA	NULL
glycosylase	NULL
,	NULL
nor	NULL
have	NULL
we	NULL
been	NULL
able	NULL
to	NULL
copurify	NULL
any	NULL
specific	NULL
UDG	NULL
enzyme	NULL
activity	NULL
from	NULL
any	NULL
complexes	NULL
associated	NULL
with	NULL
p107	NULL
,	NULL
Rb	NULL
,	NULL
or	NULL
E2F	NULL
.	NULL

*	NULL
Excluding	NULL
the	NULL
possibility	NULL
of	NULL
any	NULL
cross-reaction	NULL
with	NULL
another	NULL
antigen	NULL
,	NULL
it	NULL
is	NULL
conceivable	NULL
that	NULL
the	NULL
detection	NULL
of	NULL
this	NULL
antigen	NULL
may	NULL
represent	NULL
either	NULL
a	NULL
modified	NULL
enzymatically	NULL
inactive	NULL
form	NULL
of	NULL
UDG	NULL
or	NULL
is	NULL
an	NULL
alternative	NULL
gene	NULL
product	NULL
.	NULL

We	NULL
suspect	NULL
that	NULL
the	NULL
activity	NULL
of	NULL
E2F-1	NULL
,	NULL
potentially	NULL
mediated	NULL
through	NULL
physical	NULL
interactions	NULL
with	NULL
UDG	NULL
,	NULL
may	NULL
preclude	NULL
DNA	NULL
enzymatic	NULL
activity	NULL
of	NULL
UDG	NULL
and	NULL
could	NULL
indicate	NULL
the	NULL
expression	NULL
of	NULL
an	NULL
altered	NULL
or	NULL
processed	NULL
protein	NULL
encoded	NULL
by	NULL
a	NULL
UDG	NULL
gene	NULL
.	NULL

Additionally	NULL
,	NULL
the	NULL
notion	NULL
that	NULL
activities	NULL
expressed	NULL
by	NULL
UDG	NULL
may	NULL
represent	NULL
different	NULL
enzymatic	NULL
and	NULL
cellular	NULL
functions	NULL
through	NULL
the	NULL
selective	NULL
expression	NULL
of	NULL
distinct	NULL
domains	NULL
of	NULL
the	NULL
UDG	NULL
protein	NULL
could	NULL
be	NULL
supported	NULL
through	NULL
the	NULL
previous	NULL
examination	NULL
of	NULL
the	NULL
37	NULL
kDa	NULL
Ref-1	NULL
protein	NULL
(	NULL
52	NULL
)	NULL
.	NULL

It	NULL
was	NULL
shown	NULL
that	NULL
Ref-1	NULL
can	NULL
mediate	NULL
AP1	NULL
DNA	NULL
binding	NULL
and	NULL
transcriptional	NULL
activities	NULL
through	NULL
the	NULL
enzymatic	NULL
reduction	NULL
of	NULL
a	NULL
conserved	NULL
cysteine	NULL
residue	NULL
required	NULL
for	NULL
DNA	NULL
binding	NULL
of	NULL
both	NULL
the	NULL
Fos	NULL
and	NULL
Jun	NULL
transcription	NULL
factors	NULL
,	NULL
as	NULL
well	NULL
as	NULL
encode	NULL
specific	NULL
AP	NULL
endonuclease	NULL
activity	NULL
through	NULL
separate	NULL
and	NULL
non-overlapping	NULL
domains	NULL
of	NULL
the	NULL
Ref-1	NULL
protein	NULL
(	NULL
56	NULL
)	NULL
.	NULL

Through	NULL
this	NULL
modeled	NULL
analogy	NULL
,	NULL
we	NULL
speculate	NULL
that	NULL
the	NULL
enzymatic	NULL
mechanisms	NULL
employed	NULL
by	NULL
UDG	NULL
may	NULL
remotely	NULL
resemble	NULL
that	NULL
of	NULL
the	NULL
Ref-1	NULL
protein	NULL
.	NULL

We	NULL
intend	NULL
to	NULL
map	NULL
the	NULL
domain	NULL
(	NULL
s	NULL
)	NULL
of	NULL
UDG	NULL
responsible	NULL
for	NULL
the	NULL
growth-delayed	NULL
phenotype	NULL
to	NULL
determine	NULL
if	NULL
this	NULL
is	NULL
linked	NULL
,	NULL
in	NULL
any	NULL
way	NULL
,	NULL
to	NULL
both	NULL
E2F-mediated	NULL
transcription	NULL
and	NULL
enzymatic	NULL
DNA	NULL
repair	NULL
function	NULL
.	NULL

Acknowledgments-We	NULL
are	NULL
grateful	NULL
to	NULL
Drs	NULL
.	NULL

W.	NULL
Kaelin	NULL
,	NULL
R.	NULL
Girling	NULL
,	NULL
S.	NULL
Caradonna	NULL
,	NULL
and	NULL
I.	NULL
Belarzi	NULL
for	NULL
their	NULL
generous	NULL
gifts	NULL
of	NULL
DNA	NULL
reagents	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Drs	NULL
.	NULL

T.	NULL
Moran	NULL
of	NULL
the	NULL
Hybridoma	NULL
Core	NULL
Facility	NULL
and	NULL
S.	NULL
Arkin	NULL
of	NULL
the	NULL
Flow	NULL
Cytometric	NULL
Core	NULL
Facility	NULL
of	NULL
the	NULL
Mount	NULL
Sinai	NULL
School	NULL
of	NULL
Medicine	NULL
for	NULL
helpful	NULL
comments	NULL
and	NULL
suggestions	NULL
and	NULL
Drs	NULL
.	NULL

N.	NULL
S.	NULL
LeLeiko	NULL
and	NULL
E.	NULL
Johnson	NULL
for	NULL
comments	NULL
and	NULL
criticism	NULL
of	NULL
this	NULL
manuscript	NULL
.	NULL

We	NULL
acknowledge	NULL
Dr.	NULL
K.	NULL
Hirshhorn	NULL
,	NULL
former	NULL
chairman	NULL
of	NULL
the	NULL
Department	NULL
of	NULL
Pediatrics	NULL
,	NULL
for	NULL
his	NULL
advice	NULL
and	NULL
support	NULL
of	NULL
our	NULL
Laboratory	NULL
during	NULL
the	NULL
course	NULL
of	NULL
this	NULL
study	NULL
.	NULL

REFERENCES	NULL
.	NULL

Muller	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
and	NULL
Caradonna	NULL
,	NULL
S.	NULL
(	NULL
1991	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1088	NULL
,	NULL
197-207	NULL
.	NULL

T.	NULL
(	NULL
1979	NULL
)	NULL
Prog	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

Mol	NULL
.	NULL

Bio	NULL
.	NULL

22	NULL
,	NULL
135-195	NULL
.	NULL

Friedberg	NULL
,	NULL
E.	NULL
C.	NULL
(	NULL
1985	NULL
)	NULL
DNA	NULL
Repoir	NULL
,	NULL
pp	NULL
.	NULL

141-212	NULL
,	NULL
W.	NULL
H.	NULL
Freeman	NULL
,	NULL
New	NULL
York	NULL
.	NULL

Muller	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
and	NULL
Caradonna	NULL
,	NULL
S.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
1310-1319	NULL
.	NULL

Nevins	NULL
,	NULL
J.	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
Science	NULL
258	NULL
,	NULL
424-429	NULL
.	NULL

Mudryj	NULL
,	NULL
M.	NULL
,	NULL
Hiebert	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
and	NULL
Nevins	NULL
,	NULL
J.	NULL
R.	NULL
(	NULL
1990	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

9	NULL
,	NULL
2179-2184	NULL
.	NULL

Means	NULL
,	NULL
A.	NULL
,	NULL
Slansky	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
McManhon	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Knuth	NULL
,	NULL
M.	NULL
W.	NULL
,	NULL
and	NULL
Farnham	NULL
,	NULL
P.	NULL
(	NULL
1992	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12	NULL
,	NULL
1054-1063	NULL
.	NULL

Hiebert	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
Chellappan	NULL
,	NULL
S.	NULL
P.	NULL
,	NULL
Horowitz	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
and	NULL
Nevins	NULL
J.	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
Genes	NULL
&	NULL
Dev	NULL
.	NULL

6	NULL
,	NULL
177-185	NULL
9	NULL
.	NULL

Cao	NULL
,	NULL
L.	NULL
,	NULL
Faha	NULL
,	NULL
B.	NULL
,	NULL
Dembski	NULL
,	NULL
M.	NULL
,	NULL
Tsai	NULL
,	NULL
L.-H.	NULL
,	NULL
Harlow	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Dyson	NULL
,	NULL
N.	NULL
(	NULL
1992	NULL
)	NULL
Nature	NULL
355	NULL
,	NULL
176-179	NULL
10	NULL
.	NULL

Helin	NULL
,	NULL
K.	NULL
,	NULL
Harlow	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Fattaey	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13	NULL
,	NULL
6501-6508	NULL
11	NULL
.	NULL

Shirodkar	NULL
,	NULL
S.	NULL
,	NULL
Ewen	NULL
,	NULL
M.	NULL
,	NULL
DeCaprio	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Morgan	NULL
,	NULL
J.	NULL
,	NULL
Livingston	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
and	NULL
Chittenden	NULL
,	NULL
T.	NULL
(	NULL
1992	NULL
)	NULL
Cell	NULL
68	NULL
,	NULL
157-166	NULL
12	NULL
.	NULL

Bandara	NULL
,	NULL
L.	NULL
R.	NULL
,	NULL
Adamezewski	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Hunt	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
LaThanque	NULL
,	NULL
N.	NULL
(	NULL
1991	NULL
)	NULL
Nature	NULL
352	NULL
,	NULL
249-251	NULL
13	NULL
.	NULL

Mudryj	NULL
,	NULL
M.	NULL
,	NULL
Devoto	NULL
,	NULL
S.	NULL
H.	NULL
,	NULL
Hiebert	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
Hunter	NULL
,	NULL
T.	NULL
,	NULL
Pines	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Nevins	NULL
,	NULL
J.	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
65	NULL
,	NULL
1243-1253	NULL
14	NULL
.	NULL

Devoto	NULL
,	NULL
S.	NULL
H.	NULL
,	NULL
Mudryj	NULL
,	NULL
M.	NULL
,	NULL
Pines	NULL
,	NULL
J.	NULL
,	NULL
Hunter	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Nevins	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
(	NULL
1992	NULL
)	NULL
Cell	NULL
68	NULL
,	NULL
167-176	NULL
15	NULL
.	NULL

Lees	NULL
,	NULL
E.	NULL
,	NULL
Faha	NULL
,	NULL
B.	NULL
,	NULL
Dulic	NULL
,	NULL
V.	NULL
,	NULL
Reed	NULL
,	NULL
S.	NULL
I.	NULL
,	NULL
and	NULL
Harlow	NULL
,	NULL
E.	NULL
(	NULL
1992	NULL
)	NULL
Genes	NULL
&	NULL
Dev	NULL
.	NULL

=1	NULL
@	NULL
tp	NULL
to	NULL
bo	NULL
++	NULL
go	NULL
*	NULL
M.	NULL
J.	NULL
Walsh	NULL
,	NULL
unpublished	NULL
observations	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

The	NULL
UDG	NULL
Gene	NULL
Product	NULL
Inhibits	NULL
E2F-1-mediated	NULL
Transcription	NULL
6	NULL
,	NULL
1874-1885	NULL
Pagano	NULL
,	NULL
M.	NULL
,	NULL
Dractta	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Jansen-Durr	NULL
,	NULL
P.	NULL
(	NULL
1992	NULL
)	NULL
Science	NULL
255	NULL
,	NULL
1144-1147	NULL
Hiebert	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
Blake	NULL
,	NULL
M.	NULL
,	NULL
Azizkhan	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Nevins	NULL
,	NULL
J.	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

65	NULL
,	NULL
3547-3552	NULL
Chellappan	NULL
,	NULL
S.	NULL
,	NULL
Kraus	NULL
,	NULL
V.	NULL
B.	NULL
,	NULL
Kroger	NULL
,	NULL
B.	NULL
,	NULL
Munger	NULL
,	NULL
K.	NULL
,	NULL
Howley	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
Phelps	NULL
,	NULL
W.	NULL
C.	NULL
,	NULL
and	NULL
Nevins	NULL
,	NULL
J.	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

89	NULL
,	NULL
4549-4553	NULL
Arroyo	NULL
,	NULL
M.	NULL
,	NULL
Bagchi	NULL
,	NULL
S	NULL
,	NULL
and	NULL
Raychaudhuri	NULL
,	NULL
P.	NULL
(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Bio	NULL
.	NULL

13	NULL
,	NULL
6537-6546	NULL
Moran	NULL
,	NULL
E.	NULL
(	NULL
1993	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Genet	NULL
.	NULL

Dev	NULL
.	NULL

3	NULL
,	NULL
63-70	NULL
DeFeo-Jones	NULL
,	NULL
D.	NULL
,	NULL
Huang	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
Jones	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Haskell	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Vuuocolo	NULL
,	NULL
G.	NULL
A.	NULL
,	NULL
Hanobik	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
Huber	NULL
,	NULL
H.	NULL
E.	NULL
,	NULL
and	NULL
Oliff	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Nature	NULL
852	NULL
,	NULL
251-254	NULL
Helin	NULL
,	NULL
K.	NULL
,	NULL
Lees	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Vidal	NULL
,	NULL
M.	NULL
,	NULL
Dyson	NULL
,	NULL
N.	NULL
,	NULL
Harlow	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Fattaey	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Cell	NULL
70	NULL
,	NULL
337-50	NULL
Kaelin	NULL
,	NULL
W.	NULL
G.	NULL
,	NULL
Jr.	NULL
,	NULL
Krek	NULL
,	NULL
K.	NULL
,	NULL
Sellers	NULL
,	NULL
W.	NULL
R.	NULL
,	NULL
DeCaprio	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Ajchenbaum	NULL
,	NULL
F.	NULL
,	NULL
Fuchs	NULL
,	NULL
C.	NULL
S.	NULL
,	NULL
Chittenden	NULL
,	NULL
T.	NULL
,	NULL
Li	NULL
,	NULL
Y.	NULL
,	NULL
Farnham	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Blanar	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Livingston	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
and	NULL
Flemington	NULL
,	NULL
E.	NULL
K.	NULL
(	NULL
1992	NULL
)	NULL
Cell	NULL
70	NULL
,	NULL
351-364	NULL
Shan	NULL
,	NULL
B.	NULL
,	NULL
Zhu	NULL
,	NULL
X.	NULL
,	NULL
Chen	NULL
,	NULL
P.-L.	NULL
,	NULL
Durfee	NULL
,	NULL
T.	NULL
,	NULL
Yang	NULL
,	NULL
Y.	NULL
,	NULL
Sharp	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Lee	NULL
,	NULL
W.-H.	NULL
(	NULL
1992	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12	NULL
,	NULL
5620-5631	NULL
Ivey-Hoyle	NULL
,	NULL
M.	NULL
,	NULL
Conroy	NULL
,	NULL
R.	NULL
,	NULL
Huber	NULL
,	NULL
H.	NULL
E.	NULL
,	NULL
Goodhart	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Oliff	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Heimbrook	NULL
,	NULL
D.	NULL
(	NULL
1998	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18	NULL
,	NULL
7802-7812	NULL
Lees	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Saito	NULL
,	NULL
M.	NULL
,	NULL
Vidal	NULL
,	NULL
M.	NULL
,	NULL
Valentine	NULL
,	NULL
M.	NULL
,	NULL
Look	NULL
,	NULL
T.	NULL
,	NULL
Harlow	NULL
,	NULL
E.	NULL
,	NULL
Dyson	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
Helin	NULL
,	NULL
K.	NULL
(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18	NULL
,	NULL
7813-7825	NULL
Girling	NULL
,	NULL
R.	NULL
,	NULL
Partridge	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
Bandara	NULL
,	NULL
L.	NULL
R.	NULL
,	NULL
Burden	NULL
,	NULL
N.	NULL
,	NULL
Totty	NULL
,	NULL
N.	NULL
F.	NULL
,	NULL
Hsuan	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
and	NULL
LaThangue	NULL
,	NULL
N.	NULL
(	NULL
1993	NULL
)	NULL
Nature	NULL
362	NULL
,	NULL
83-87	NULL
Helin	NULL
,	NULL
K.	NULL
,	NULL
Lees	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Vidal	NULL
,	NULL
M.	NULL
,	NULL
Dyson	NULL
,	NULL
N.	NULL
,	NULL
Harlow	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Fattaey	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Genes	NULL
&	NULL
Dev	NULL
.	NULL

7	NULL
,	NULL
1850-1861	NULL
Krek	NULL
,	NULL
W.	NULL
,	NULL
Ewen	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Shirodkar	NULL
,	NULL
S.	NULL
,	NULL
Arany	NULL
,	NULL
Z.	NULL
,	NULL
Kaelin	NULL
,	NULL
W.	NULL
G.	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
Livingston	NULL
,	NULL
D.	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
Cell	NULL
78	NULL
,	NULL
161-172	NULL
Cleaver	NULL
,	NULL
J.	NULL
E.	NULL
(	NULL
1994	NULL
)	NULL
Cell	NULL
76	NULL
,	NULL
1-4	NULL
Dutta	NULL
,	NULL
A.	NULL
,	NULL
Ruppert	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Aster	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
and	NULL
Winchester	NULL
,	NULL
E.	NULL
(	NULL
1993	NULL
)	NULL
Nature	NULL
365	NULL
,	NULL
49-53	NULL
Cormack	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
in	NULL
Short	NULL
Protocols	NULL
in	NULL
Molecular	NULL
Biology	NULL
(	NULL
Ausubel	NULL
,	NULL
F.	NULL
M.	NULL
,	NULL
Brent	NULL
,	NULL
R.	NULL
,	NULL
Kingston	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Moore	NULL
,	NULL
D.	NULL
D.	NULL
,	NULL
Seidman	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Smith	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Struhl	NULL
,	NULL
K.	NULL
,	NULL
eds	NULL
)	NULL
Second	NULL
Ed	NULL
.	NULL

,	NULL
pp	NULL
.	NULL

8.18-8.25	NULL
,	NULL
Greene	NULL
Publishing	NULL
Associates	NULL
and	NULL
Wiley-Interscience	NULL
,	NULL
New	NULL
York	NULL
Walsh	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Sanchez-Pozo	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
LeLeiko	NULL
,	NULL
N.	NULL
S.	NULL
(	NULL
1990	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10	NULL
,	NULL
4356-4364	NULL
Skainik	NULL
,	NULL
D.	NULL
G.	NULL
,	NULL
Strauss	NULL
,	NULL
E.	NULL
C.	NULL
,	NULL
and	NULL
Orkin	NULL
,	NULL
S.	NULL
H.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Bio	NULL
{	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
16736-16744	NULL
Tedder	NULL
,	NULL
T.	NULL
F.	NULL
,	NULL
and	NULL
Isaacs	NULL
,	NULL
C.	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

148	NULL
,	NULL
712-717	NULL
Dolbreare	NULL
,	NULL
F.	NULL
,	NULL
Gratzner	NULL
,	NULL
H.	NULL
,	NULL
Pallavicini	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
and	NULL
Gray	NULL
,	NULL
J.	NULL
W.	NULL
(	NULL
1983	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

80	NULL
,	NULL
5573-5577	NULL
Walsh	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Tsao	NULL
,	NULL
K.-L.	NULL
,	NULL
and	NULL
LeLeiko	NULL
,	NULL
N.	NULL
S.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
7026-7035	NULL
Kollmar	NULL
,	NULL
R.	NULL
,	NULL
Sukow	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Sponagle	NULL
,	NULL
S.	NULL
K.	NULL
,	NULL
and	NULL
Farnham	NULL
,	NULL
P.	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
2252-2257	NULL
Lu	NULL
,	NULL
J.	NULL
,	NULL
Lee	NULL
,	NULL
W.	NULL
,	NULL
Jiang	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Keller	NULL
,	NULL
E.	NULL
B	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
5391-5402	NULL
Yee	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
Raychaudhuri	NULL
,	NULL
P.	NULL
,	NULL
Jokoi	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Nevins	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

9	NULL
,	NULL
578-585	NULL
Huber	NULL
,	NULL
H.	NULL
E.	NULL
,	NULL
Edwards	NULL
,	NULL
G.	NULL
,	NULL
Goodhart	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Patrick	NULL
,	NULL
D.	NULL
R.	NULL
,	NULL
Huang	NULL
,	NULL
P.	NULL
S.	NULL
(	NULL
1993	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

90	NULL
,	NULL
3594-3598	NULL
Hunter	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Pines	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Cell	NULL
66	NULL
,	NULL
1071-1074	NULL
Girard	NULL
,	NULL
F.	NULL
,	NULL
Strausfeld	NULL
,	NULL
U.	NULL
,	NULL
Fernandez	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Lamb	NULL
,	NULL
N.	NULL
J.	NULL
C.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
67	NULL
,	NULL
1169-1179	NULL
Goodrich	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
Wang	NULL
,	NULL
N.	NULL
P.	NULL
,	NULL
Qian	NULL
,	NULL
Y.-W.	NULL
,	NULL
Lee	NULL
,	NULL
E.	NULL
Y.-H.	NULL
P.	NULL
,	NULL
and	NULL
Lee	NULL
,	NULL
W.-H.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
67	NULL
,	NULL
293-302	NULL
Templeton	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Park	NULL
,	NULL
S.	NULL
H.	NULL
,	NULL
Lanier	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Weinberg	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

88	NULL
,	NULL
3033-3037	NULL
Qin	NULL
,	NULL
X.-Q	NULL
.	NULL

,	NULL
Chittenden	NULL
,	NULL
T.	NULL
,	NULL
Livingston	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Kaelin	NULL
,	NULL
W.	NULL
G.	NULL
(	NULL
1992	NULL
)	NULL
Genes	NULL
&	NULL
Dev	NULL
.	NULL

6	NULL
,	NULL
953-964	NULL
Seto	NULL
,	NULL
E.	NULL
,	NULL
Usheva	NULL
,	NULL
A.	NULL
,	NULL
Zambetti	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
Mamand	NULL
,	NULL
J.	NULL
,	NULL
Horikoshi	NULL
,	NULL
N.	NULL
,	NULL
Weinmann	NULL
,	NULL
R.	NULL
,	NULL
Levine	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
and	NULL
Shenk	NULL
,	NULL
T.	NULL
(	NULL
1992	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

89	NULL
,	NULL
12028-12032	NULL
Xanthoudakis	NULL
,	NULL
S.	NULL
,	NULL
Miao	NULL
,	NULL
G.	NULL
,	NULL
Wang	NULL
,	NULL
F.	NULL
,	NULL
Pan	NULL
,	NULL
Y.-C.	NULL
E.	NULL
,	NULL
and	NULL
Curran	NULL
,	NULL
T.	NULL
(	NULL
1992	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

11	NULL
,	NULL
3323-3335	NULL
Liu	NULL
,	NULL
(	NULL
1993	NULL
)	NULL
Mol	NULL
Cell	NULL
.	NULL

Biol	NULL
.	NULL

13	NULL
,	NULL
3291-3300	NULL
Schaeffer	NULL
,	NULL
L.	NULL
,	NULL
Roy	NULL
,	NULL
R.	NULL
,	NULL
Humbert	NULL
,	NULL
S.	NULL
,	NULL
Moncollin	NULL
,	NULL
V.	NULL
,	NULL
Vermeulen	NULL
,	NULL
W.	NULL
,	NULL
Hoeijmakers	NULL
,	NULL
J.	NULL
H.	NULL
J.	NULL
,	NULL
Chambon	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Egly	NULL
,	NULL
J.-M.	NULL
(	NULL
1998	NULL
)	NULL
Science	NULL
260	NULL
,	NULL
58-63	NULL
Wu	NULL
,	NULL
X.	NULL
,	NULL
and	NULL
Levine	NULL
,	NULL
A.	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

91	NULL
,	NULL
3602-3606	NULL
Abate	NULL
,	NULL
C.	NULL
,	NULL
Luk	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Curran	NULL
,	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11	NULL
,	NULL
3624-3632	NULL
Kim	NULL
,	NULL
S.-J	NULL
.	NULL

,	NULL
Onwuta	NULL
,	NULL
U.	NULL
S.	NULL
,	NULL
Lee	NULL
,	NULL
Y.	NULL
I.	NULL
Li	NULL
,	NULL
R.	NULL
,	NULL
Botchan	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
and	NULL
Robbins	NULL
,	NULL
P.	NULL
D.	NULL
(	NULL
1992	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12	NULL
,	NULL
2455-2463	NULL
Shan	NULL
,	NULL
B.	NULL
,	NULL
Chang	NULL
,	NULL
C.-Y	NULL
.	NULL

,	NULL
Jones	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Lee	NULL
,	NULL
W.-H.	NULL
(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
299-309	NULL
Templeton	NULL
,	NULL
D.	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12	NULL
,	NULL
435-443	NULL
Xanthoudakis	NULL
,	NULL
S.	NULL
,	NULL
Miao	NULL
,	NULL
G.	NULL
G.	NULL
,	NULL
and	NULL
Curran	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

91	NULL
,	NULL
23-27	NULL

